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ABSTRACT OF DISSERTATION 
 
BEYOND PEROXISOME: ABCD2 MODIFIES PPAR SIGNALING AND 
IDENTIFIES A SUBCLASS OF PEROXISOMES IN MOUSE ADIPOSE TISSUE 
 
ABCD2 (D2) has been proposed as a peroxisomal long-chain acyl-CoA transporter that is 
essential for very long chain fatty acid metabolism. In the livers of mice, D2 is highly 
induced by fenofibrate, a PPARligand that has been widely used as a lipid lowering 
agent in the treatment of hypertriglyceridemia. To determine if D2 is a modifier of fibrate 
responses, wild-type and D2 deficient mice were treated with fenofibrate for 14 days. The 
absence of D2 altered expression of gene clusters associated with lipid metabolism, 
including PPARsignaling. Using 3T3-L1 adipocytes, which express high levels of D2, 
we confirmed that knock-down of D2 modified genomic responses to fibrate treatment. 
We next evaluated the impact of D2 on effects of fibrates in a mouse model of diet-
induced obesity. Fenofibrate treatment opposed the development of obesity, 
hypertriglyceridemia, and insulin resistance. However, these effects were unaffected by 
D2 genotype. We concluded that D2 can modulate genomic responses to fibrates, but that 
these effects are not sufficiently robust to alter the effects of fibrates on diet-induced 
obesity phenotypes. 
Although proposed as a peroxisomal transporter, the intracellular localization of D2, 
especially in adipose tissue, has not been validated with direct experimental evidence. 
Sequential centrifugation of mouse adipose homogenates generated a fraction enriched 
with D2, but lacked well-known peroxisome markers including catalase, PEX19, and 
ABCD3 (D3). Electron microscopic imaging of this fraction confirmed the presence of 
D2 protein on an organelle with evidence of a dense matrix and a diameter of ~200 nm, 
the typical structure and size of a microperoxisome. D2 and PEX19 antibodies 
recognized distinct structures in mouse adipose. Immunoisolation of the D2-containing 
compartment from adipose tissue confirmed the scarcity of PEX19. Proteomic profiling 
of the D2 compartment revealed the presence of proteins associated peroxisome, 
endoplasmic reticulum (ER), and mitochondria. We conclude that D2 is localized to a 
distinct subclass of peroxisomes that lack many peroxisome proteins and may physically 
associate with mitochondria and the ER.  
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CHAPTER 1: INTRODUCTION 
1.1 METABOLIC SYNDROME, DYSLIPIDEMIA AND CARDIOVASCULAR 
DISEASE 
1.1.1 Metabolic syndrome 
1.1.1.1 Definition 
Metabolic syndrome (MtS) is a group of medial disorders that raise the risk of developing 
type 2 diabetes and cardiovascular disease [1]. There have been several definitions of 
metabolic syndrome historically. The most commonly used criteria were proposed by 
World Health Organization (WHO) [2], the European Group for the study of Insulin 
Resistance (EGIR) [3], the National Cholesterol Education Program Adult Treatment 
Panel III (NCEP ATP III) [4], American Association of Clinical Endocrinologists (AACE) 
[5], and the International Diabetes Federation (IDF) [1]. Although the criteria of each 
definition slightly differ (Table 1.1), the common characteristics include central obesity, 
atherogenic dyslipidemia, high blood pressure, and insulin resistance.  
1.1.1.2 Epidemiology 
The international prevalence of MtS ranges from less than 10% to 84%, depending on the 
region, sex, age, race and ethnicity of the population studied [6-9]. The MtS is 
significantly associated with higher economic status, sedentary lifestyle, and high body 
mass index and quite prevalent in developed countries such as US and Europe [1]. The 
observed prevalence of MtS is highly correlated with obesity, with the occurrence of 5% 
in normal weight, 22% in overweight, and 60% in obese populations [10]. The prevalence 
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of MtS varies from 8% to 43% in men whereas from 7% to 56% in women around the 
world [9]. The occurrence of MtS increases with age, with 40–59 years of age about three 
times as prevalent as those 20–39 years of age, 60 years of age and over more than four 
times as prevalent in males and six times in females [11].  
 
Table 1.1 Clinical diagnostic criteria for metabolic syndrome [12]. 
1.1.1.3 Central obesity 
Central obesity is clinically characterized as excessive abdominal or visceral fat 
deposition around the stomach and abdomen. Generally, obesity is due the excessive 
consumption of high energy food and lack of physical activity. Although obesity is a risk 
factor for insulin resistance, type 2 diabetes and cardiovascular disease, some obese 
patients are “protected” from these disease by unknown mechanism [13]. On the other 
Clinical Diagnostics WHO EGIR ATPIII AACE IDF
Insulin Resistance
IGT, IFG, T2DM, or
lowered insulin
Sensitivity
plus any 2 of the
following
Plasma insulin >75th
percentile
plus any 2 of the
following
None, but any 3 of
the following
5 features
IGT or IFG
plus any of
thefollowing based
on the clinical
judgment
None
Central Obesity
Men: waist-to-hip
ratio >0.90;
women: waist-to-hip
ratio >0.85 and/or
BMI > 30 kg/m2
WC ≥94 cm in men
or ≥80 cm in women
WC ≥102cm inmen
or ≥88 cm in women
BMI ≥ 25 kg/m2
IncreasedWC
(population specific)
plus any 2 of the
following
Dislypidemia
TGs ≥150mg/dL
and/or HDL-C
<35 mg/dL in men or
<39 mg/dL in women
TGs ≥150mg/dL
and/or HDL-C
<39 mg/dL in men or
women
TGs ≥150mg/dL
HDL-C <40mg/dL in
men or <50mg/dL in
women
TGs ≥150mg/dL and
HDL-C <40mg/dL in
men or <50mg/dL in
women
TGs ≥150mg/dL or
on TGs Rx.
HDL-C <40mg/dL in
men or <50mg/dL in
women or on HDL-C
Rx
Hypertension ≥140/90mmHg
≥140/90mmHg or on
hypertension Rx
≥130/85mmHg ≥130/85mmHg
≥130mmHg systolic
or ≥85 mm Hg
diastolic or on
hypertension Rx
Hyperglycemia IGT, IFG, or T2DM
IGT or IFG (but not
diabetes)
>110mg/dL (includes
diabetes)
IGT or IFG (but not
diabetes)
≥100mg/dL (includes
diabetes)
Other
Microalbuminuria:
Urinary excretion rate
of >20mg/min or
albumin: creatinine
ratio of >30mg/g.
Other features of
insulin resistance
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hand, individuals with excess of visceral fat is at substantially higher risk of insulin 
resistance and MtS compared with those with similar amount of total body fat, indicating 
a strong correlation of central obesity and MtS [14, 15]. However, it is still controversial 
whether visceral fat is a causal factor or just a biomarker of MtS.   
In centrally obese patients, the intra-abdominal adipocytes are characterized by a 
hypertrophied and hyperlipolytic state that is resistant to the effects of insulin [16, 17]. 
This leads to increased non-esterified fatty acid (NEFA) flux to the liver and may impair 
liver metabolism. In a diet-induced visceral obesity canine model, hepatic insulin 
resistance was observed with respect to glucose production [18]. Excessive visceral fat is 
also correlated with circulating NEFA and may contribute to peripheral tissue insulin 
resistance  [19].  An acute exposure to high levels of NEFA induces insulin resistance in 
skeletal muscle by inhibiting glucose uptake whereas chronic exposure impairs pancreatic 
-cell function [20]. 
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Figure 1.1 Central obesity and ectopic lipid accumulation in peripheral tissues [21]. 
Excessive visceral fat accumulation might lead to ectopic lipid accumulation in 
peripheral tissues such as skeletal muscle, heart and liver, which may eventually increase 
the risk of metabolic syndrome.  
 
Besides serving as a lipid reservoir, adipose tissue is also an important endocrine organ. 
The signal molecules secreted from adipose tissue includes TNF, IL-6, C-reactive 
protein (CRP), plasminogen activator inhibitor-1 (PAI-1), adipsin, acylation stimulating 
protein (ASP), adiponectin, leptin and resistin [22]. Abdominally obese patients with 
excess of visceral fat have elevated plasma CRP, TNF, and IL-6 concentrations and 
reduced adiponectin concentrations [23]. CRP is an inflammatory marker that has been 
demonstrated as an independent predictor of the occurrence of future cardiovascular 
disease [24]. TNF is a paracrine mediator in adipocytes and have been suggested to 
induce adipocyte apoptosis and promote insulin resistance by inhibiting the insulin 
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receptor substrate 1 signaling pathway [25, 26]. This further tends to exacerbate the 
NEFA release and induce dyslipidemia [27]. IL-6 has both inflammatory and anti-
inflammatory actions. IL-6 impairs insulin sensitivity and also serves as a major 
determinant of the hepatic production of CRP. IL-6 also suppresses lipoprotein lipase 
activity [28]. Adiponectin has been shown as a strong inverse independent risk factor for 
cardiovascular disease and therefore considered as to be ‘protective’ [29]. Adiponectin 
has multifaceted functions including, but not limited to, insulin sensitizing, inhibiting 
hepatic gluconeogenesis, promoting glucose transport and fatty acid oxidation in muscles, 
and antagonism of TNF. Overall, central obesity is tightly associated with 
altered NEFA metabolism and adipose endocrine that together promote the development 
of MtS.  
1.1.1.4 Insulin resistance 
In the wild environment, nutrient sources are often scarce and caloric demands constantly 
change. Faced with this challenge, animals develop mechanisms to promote anabolism 
when energy consumption is excessive and become catabolic when demands override 
consumption. Insulin acts an efficient solution to adapt to this challenge. However, in 
modern human society, the common lifestyle has greatly altered with abundant caloric 
supply but very little caloric demands. Obesity is now an epidemic and often associated 
with other diseases including metabolic syndrome, type 2 diabetes, nonalcoholic fatty 
liver disease and cardiovascular disease. Insulin resistance is found with the pathogenesis 
for many of these modern diseases.  
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Insulin resistance is defined as a pathological condition in which a normal insulin 
concentration fails to produce an adequate response in peripheral tissues such as muscle, 
adipose and liver, which is a key feature of type 2 diabetes. Insulin resistance is a major 
characteristic of MtS and leads to compensatory elevated insulin secretion from 
pancreatic -cells. Intensive insulin therapy may compensate for insufficient insulin 
action and maintain normal glycemic levels. However, this therapy increases the body 
weight and the risk of developing cardiovascular disease [33]. Several mechanisms have 
been proposed to explain the pathogenesis of insulin resistance. Three representative 
mechanisms include ectopic lipid accumulation, ER stress and systemic inflammation 
[34].  
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Figure 1.2 Insulin action in normal and type 2 diabetes conditions [34]. In normal 
insulin sensitive conditions, during the fed state, dietary carbohydrate leads to elevated 
plasma glucose levels and triggers insulin secretion from pancreatic  cells. Circulating 
insulin acts on peripheral tissues including liver, skeletal muscle and adipose. In the liver, 
insulin increases glycogen synthesis while decreasing gluconeogenesis, and promotes 
lipogenesis. In the skeletal muscle, insulin promotes glucose transport and glycogen 
synthesis. In the adipose, insulin promotes triglyceride synthesis while inhibiting lipolysis. 
During the fasted state, low plasma glucose levels prohibit insulin secretion and therefore 
plasma insulin level is low. This promotes glycogenolysis and gluconeogenesis and 
inhibits lipogenesis in the liver, permits the glycogenolysis in the muscle and lipolysis in 
the adipose. In type 2 diabetic conditions, the insulin signaling is impaired due to ectopic 
lipid accumulation in peripheral tissues (impaired pathways indicated by ‘x’). The results 
are decreased hepatic glycogen synthesis and increased gluconeogenesis and lipogenesis, 
decreased glucose transport and glycogen synthesis in liver and increased lipolysis in 
adipose in both fed and fasted states.   
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It is widely accepted that the ectopic lipid accumulation is associated with insulin 
resistance. Early studies demonstrated that acute lipid infusions decreased myocellular 
glucose utilization by inhibition of pyruvate dehydrogenase, leading to reductions in 
glucose oxidation and accumulation of glycolytic intermediates [35, 36]. In chronic 
disease states, however, insulin resistance in skeletal muscle can be attributed to impaired 
insulin signaling and therefore decreased glucose transport due to impaired GLUT4 
translocation, rather than inhibited glycolysis [37, 38]. Since lipids can either circulate in 
plasma or accumulate within insulin responsive tissues, there were debates concerning 
which lipids are responsible for insulin resistance. Studies in normal weight, non-diabetic 
adults have shown that intramyocellular lipid content is a much stronger predictor of 
muscle insulin resistance than circulating fatty acids [39]. In normal rates infused with 
lipid emulsion, muscle insulin resistance developed concordantly with the accumulation 
of intramyocellular diacylglycerol (DAG) and impaired glucose uptake 3-4 hours after 
the lipid infusion [40]. Insulin resistance occurred independently of changes in muscle 
triglyceride (TG) content, thus dissociating the TG concentrations from insulin resistance 
and proposing DAG as the inducer [41]. DAG, a signaling intermediate that activates 
protein kinase C (PKC) family, was associated with the activation of novel PKCin these 
experiments. The link between DAG-mediated activation of novel PKC and muscle 
insulin resistance has been confirmed in human studies, although with some difference in 
the novel PKC isoforms that was activated [42].  
Ectopic lipid accumulation in liver, also known as steatosis is the most common chronic 
live disease in US. Dietary caloric restriction rapidly reduces hepatic steatosis in patients 
with poorly controlled type 2 diabetes [43, 44]. After 12 weeks on a hypocaloric diet, 
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these patients experienced rapid decrease in liver fat content, associated with 
normalization in hepatic insulin sensitivity and reductions in fasting hyperglycemia. The 
relationship of hepatic lipid accumulation and insulin resistance has been supported with 
increasing evidence in genetic rodent models. Lipoprotein lipase (LPL) is a key enzyme 
that hydrolyzes plasma TG and promotes the tissue uptake of released free fatty acids 
through fatty acid transport protein (FATP) and CD36. The overexpression of LPL in 
liver leads to hepatic steatosis and hepatic insulin resistance [45, 46]. The overexpression 
of hepatic CD36 causes NAFLD even in mice fed with regular chow-diet [47]. Deletion 
of FATP2 or FATP5 reduces hepatic fatty acid transport and protects against hepatic 
steatosis and glucose intolerance [48, 49].  
1.1.1.5 Hypertension 
Individuals with hypertension have two to three fold increased risk for cardiovascular 
disease compared with non-hypertensive individuals. Essential hypertension is often 
observed associated with other metabolic disorders, most commonly obesity, insulin 
resistance and dyslipidemia [50]. At least 75% of the incidence of hypertension is 
estimated to have a direct relation to obesity [51]. Several mechanisms have been 
proposed to explain the close relationship between hypertension and obesity. Insulin has 
been proposed as a mediator for hypertension in obese patients due to the fact that it 
stimulates the sympathetic nervous system (SNS) and its secretion is considerably 
elevated by obesity [52-54]. This is supported by studies demonstrating concomitant 
decreases in blood pressure and SNS activity when insulin is lowered due to low energy 
diets [55]. There are studies suggesting that hyperglycemia and hyperinsulinemia 
increase the expression of angiotensinogen, angiotensin II, and the ATI receptor and 
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therefore activate the renin angiotensin system (RAS). The RAS may give rise to the 
development of hypertension in insulin resistant patients [56].  
1.1.2 Dyslipidemia and cardiovascular disease 
Atherogenic dyslipidemia comprises a higher proportion of small light-density 
lipoprotein (LDL) particles, reduced high-density lipoprotein (HDL)-cholesterol and 
increase triglycerides (TG) [57]. It is commonly seen in patients with obesity, the 
metabolic syndrome, insulin resistance and type 2 diabetes and has been recognized as an 
important marker for the increased cardiovascular disease risk [58, 59]. Both lifestyle 
changes and pharmacological treatments are recommended to control the development of 
dyslipidemia in patients with metabolic syndrome and type 2 diabetes. The National 
Cholesterol Education Program (NCEP) adult Treatment Panel (ATP) III recommended 
lifestyle changes including reduced intake of saturated fats and cholesterol, intake of 
dietary options to enhance lowering of LDL cholesterol, weight control, and increased 
physical activity [60]. For individuals at high risk of or currently having developing 
cardiovascular disease, or persistent atherogenic dyslipidemia, pharmacotherapy may be 
necessary.  
Statins are a class of drugs that are effective in lowering cholesterol levels, improving 
dyslipidemia and decreasing the risks of cardiovascular diseases. They act as reversible, 
competitive inhibitors of HMG-CoA reductase, the rate-limiting enzyme for cholesterol 
biosynthesis. By reducing cholesterol synthesis and decreasing the intracellular 
cholesterol pool, the statins stimulate the upregulation of cell surface LDL receptors and 
promote the clearance of apoB100-containing lipoproteins (VLDL, VLDL remnants, IDL 
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and LDL) [61]. Other functions of statins include inhibiting hepatic VLDL secretion, 
lowering plasma TG levels, increasing apoA-I expression and HDL secretion [61]. 
Statins are the first-line option for lowering LDL cholesterol [60]. The LDL cholesterol 
reducing capacity of specific statins differs and can be summarized as follows: 
rosuvastatin 45–63% (5–40mg/day); atorvastatin 26–60% (10–80 mg/day); simvastatin 
26–47% (10–80 mg/day); lovastatin 21–42% (10–80mg/day); fluvastatin 22–36%(10–
20mg/day); and pravastatin 22–34% (10–80 mg/day). Therefore, the selection of specific 
statin and dose are generally based on the targeted reduction of LDL cholesterol [62].  
Ezetimibe is primarily used as a secondary therapy to statins to further reduce LDL 
cholesterol. It acts by binding to the Niemann-Pick C1-like 1 protein (NPC1L1), a sterol 
transporter that is responsible for cholesterol and phytosterol absorption in intestine, and 
therefore inhibiting cholesterol absorption [63, 64]. Ezetimibe alone decreases plasma 
LDL cholesterol by 20% and has an additive lowering effect when combined with statins 
[65, 66]. Although there is no clinical trial evidence that ezetimibe treatment alone 
beneficially impacts the risk for cardiovascular an event, statin/ezetimibe combination 
offers an option for patients who don’t tolerate moderate to high doses of statins.  
Bile acid sequestrants (BAS) are a group of anion exchange resins that bind bile acids in 
the gastrointestinal tract. BASs are polymeric compounds that are not absorbed by the gut. 
Thus, BAS along with any bile acids bound to the drug are excreted through feces, which 
prevent the reabsorption of bile acids across the terminal ileum and lower their 
concentration in the enterohepatic circulation [61]. With reduced bile acids reabsorbed, 
there is increased consumption of cholesterol due to the upregulation of 7-a-hydroxylase, 
the rate-limiting enzyme for the conversion of cholesterol into bile acids. With increased 
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intrahepatic cholesterol consumption, hepatocytes increase their surface expression of 
LDL receptors and therefore promote the clearance of apoB100-containing lipoproteins 
from plasma. The BAS decrease plasma LDL cholesterol by 15-30% and increase HDL 
cholesterol by 3-5%. Statins should be used in combination with BAS because BAS 
stimulate HMG-CoA reductase activity and offset the effects over time.  
Niacin, also known as nicotinic acid, vitamin B3, is the oldest lipid lowering drug which 
reduces LDL cholesterol, TG and increases HDL cholesterol [67]. The efficacy of niacin 
therapy in reducing cardiovascular events was first described in the Coronary Drug 
Project [68].  Niacin alone or combined with other lipid lowering drugs can significantly 
reduce the risk of cardiovascular disease [69]. The mechanism of niacin effects is 
complex and not completely characterized. Niacin stimulates hepatic production of 
apolipoprotein A1 and HDL and inhibits HDL uptake and catabolism by hepatocytes [70, 
71]. Niacin decreases fatty acids flux from visceral adipose to liver by inhibiting 
hormone-sensitive lipase activity and therefore reduces the substrate for hepatic TG 
synthesis [72]. It also inhibits diacylglycerol acyltransferase, an enzyme that esterifies 
fatty acid to glycerol, and therefore reduces TG formation with hepatocytes and VLDL 
formation [73].  
 
1.2 PPAR AND FIBRATES 
1.2.1 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS 
Introduction 
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Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor 
proteins that functions as transcription factors [74]. When activated by endogenous 
and/or synthetic ligands, PPARs bind to the peroxisome proliferator response element 
(PPRE) motifs of regulated gene promoter regions and induce the transcription of 
downstream target genes that have various biological roles [75].  
Peroxisome proliferation was first reported in rats in the 1960s [76]. A number of 
compounds were later discovered to induce the peroxisome proliferation and named as 
peroxisome proliferators. The first receptor for peroxisome proliferators was cloned from 
mouse liver in 1990 and named as peroxisome proliferator-activated receptor [77]. 
Shortly afterwards, it was realized that the PPARs are a group of three receptors , / 
and . They all function as transcription factors and regulate the expression of genes 
involved in a variety of biological processes including glucose and lipid metabolism, 
energy homeostasis, insulin sensitivity, immune responses, and cell growth and cell 
differentiation [79]. A variety of endogenous ligands for PPARs have been identified 
while a series of synthetic agonists have been discovered and commercialized [80]. Based 
on the tissue distribution and ligand specificity, the activation of PPARs usually results in 
diverse effects including adipogenesis, fatty acid oxidation, and anti-inflammation [81]. 
All three isoforms of PPAR possesses similar structures. They contain four functional 
domains: A/B, C, D and E/F. The N-terminal domain (A/B) is responsible for the 
phosphorylation of the receptor [82]. The C domain is the DNA binding domain that is 
required for the binding of the receptor to peroxisome-proliferator response element 
(PPRE) in the promoter region of target genes [83]. The D domain or co-FBD is the site 
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for co-factors coupling. The ligand-binding domain or E/F domain is responsible for 
specific ligand binding and activation of PPARs [84]. AF-2 domain is associated with 
E/F domain and promotes the recruitment of cofactors for the initiation of gene 
transcription process [84]. 
 
Figure 1.3: Functional domains of PPARs [85]. The PPARs consist of four functional 
domains. The N-terminal region contains the A/B domain that is preceded with AF-1 
which is responsible for phosphorylation. C domain (DBD) is responsible for DNA 
binding. The D domain is the region of cofactors binding (Co-FBD).  The E/F domain is 
the ligand binding domain (LBD) followed by the AF-2 which recruits cofactors for gene 
transcription. 
 
PPAR forms a heterodimer with RXR and binds to the PPRE region of target gene’s 
promoter. In the absence of ligands, the activation of transcription is blocked by 
associated corepressor proteins. These proteins include G-protein pathway suppressor 2 
(GPS2), nuclear receptor corepressors (NCoR), and histone deacetylases (HDAC) [86, 
87]. Ligand binding leads to the dissociation of the corepressor proteins and recruits 
coactivators such as PPAR coactivator (PGC-1), the histone acetyltransferase p300, 
CREB binding protein (CBP), and steroid receptor coactivator (SRC)-1. Formation of the 
PPAR activation complex causes histone modification (e.g., through acetylation) and 
initiation of gene transcription [88, 89].  
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Figure 1.4: PPAR regulates gene transcription [85]. Without ligand binding, the PPAR 
is in the inactivated state and interacts with the corepressor. The complex inhibits the 
initiation of transcription through its histone deacetylase activity. With ligand binding, 
PPAR is activated and heterodimerizes with RXR. The heterodimer recruits coactivators 
and promotes gene transcription due to its histone acetylase activity. 
 
PPAR 
PPAR is expressed in immune cells, mucosa of colon and cecum, placenta, but is most 
widely expressed in adipose tissue. PPARis the master regulator for differentiation and 
functioning of adipocytes [90].  There are three isoforms of PPARidentified. All three 
isoforms are derived from the same gene but transcribed using alternative promoters [91, 
92]. PPAR 1 is ubiquitously expressed, while PPAR2 is restricted to adipose tissue and 
PPAR3 is abundant in adipose tissue, macrophages and large intestine [93, 94]. Genetic 
ablation studies in cells have shown that PPAR1 has adipogenic action but PPAR2 is 
more potent in this function [95].  
Like most nuclear receptors, functions as a ligand-activated transcription factor. The 
biological ligands for PPAR are still not characterized. It has been shown that 
polyunsaturated fatty acids and related molecules can activate PPARalthough the 
response to native fatty acids is poor . Certain oxidized fatty acids found in oxidized 
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LDL activate PPAR with increased potency and efficacy relatively and are present 
significantly in atherosclerotic lesions [97]. However, it is unclear if oxidized fatty acids 
are activators in other tissues. Nitrated fatty acids and lysophosphatidic acid have also 
been reported to activate PPAR . The impact of these molecules in 
PPARbiology needs further validation.  
Thiazolidinediones (TZD) are a class of synthetic agonists that activate PPARand are 
known for their anti-diabetic effects. The TZDs were initially discovered to lower 
glucose levels in rodents. They were later confirmed to improve insulin sensitivity in 
human subjects [100]. Rosiglitazone and pioglitazone are currently widely used in clinic 
for the treatment of type 2 diabetes. TZDs take their effects by primarily acting on 
adipose tissue through a ‘lipid steal’ mechanism [101, 102]. Type 2 diabetes is associated 
with elevated plasma free fatty acids (FFA) and ectopic lipid accumulation in peripheral 
tissues other than adipose, such as liver and skeletal muscle. Activation of PPAR in 
adipose tissue increases its capability to store dietary fatty acids through upregulation of 
aP2, LPL, CD36, FATP, PEPCK and the glycerol transporter aquaporin 7. This results in 
the shift of fatty acids into adipose from other peripheral tissues where ectopic lipid 
accumulation has deleterious effects on insulin action. Another mechanism by TZDs 
sensitize insulin response is by altering the production of adipokines. TZD administration 
in rodents and humans induced the mRNA and plasma protein levels of adiponectin, of 
which amount is inversely correlated with insulin sensitivity [103-105]. Activation of 
PPAR in adipocytes is also associated with decreased TNFand resistin which cause 
insulin resistance [106].  
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Figure 1.5 Thiazolidinedione (TZD) activates PPARγ in adipose tissue and increases 
insulin sensitivity [90]. PPARγ activation in adipose tissue promotes lipid uptake from 
plasma and storage in adipocytes. Activation of PPARγ also alters the production of 
adipokines (i.e. adiponectin, TNFα, MCP-1, and resistin). This leads to suppression of 
hepatic glucose uptake and stimulation of skeletal muscle glucose uptake. Activation of 
PPARγ also tilts the population of macrophages toward the anti-inflammatory M2 
phenotype and reduces macrophage infiltration into adipose. FA, fatty acid; FFA, free 
fatty acid; TG, triglyceride. 
 
PPAR/ 
PPAR or  is highly expressed in many tissues including colon, small intestine, liver, 
keratinocytes, heart, adipose, spleen, skeletal muscle, lung, brain and thymus [107]. 
Although expressed all over the body, its pharmacology is less understood than the other 
subtypes [108]. PPAR is the most abundant isoform of all the three PPARs in skeletal 
muscle. Given the large percentage of skeletal muscle in whole body weight (~50%), it 
was proposed that activation of PPAR may greatly promote fatty acid catabolism in 
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skeletal muscle and therefore improve plasma lipid profiles [85]. However, very little 
evidence has been reported to support this hypothesis. Nonetheless, a number of synthetic 
compounds are being developed as selective PPAR ligands and have shown potential 
application in treating dyslipidemia. In insulin-resistant middle-aged obese rhesus 
monkey, a selective PPAR agonist GW501516 causes a dramatic increase in plasma 
HDL cholesterol and reductions in LDL and TG in a dose dependent manner, suggesting 
its hypolipidemic and antidiabetic properties [109]. In humans, however, there are 
conflicting reports as to whether PPAR polymorphisms are associated with plasma 
lipoprotein profiles [110, 111]. 
1.2 PPAR AND FIBRATES 
 PPAR
Introduction 
PPAR was the first identified PPAR isoform and named based on its ability to be 
activated by peroxisome proliferators in rodents. PPAR is expressed in numerous 
tissues including liver, kidneys, heart, skeletal muscle and brown adipose [94, 112]. 
PPAR expression is also detected in immune cells such as T-cells and macrophages 
[113, 114]. Evidence suggests that rodents and humans have similar tissue distribution 
pattern of PPAR[115, 116]  PPAR is a key modulator of fatty acid oxidation, which 
occurs in mitochondria, peroxisomes and microsomes in the liver. It controls many 
aspects of hepatic lipid metabolism, including fatty acid uptake and activation, 
intracellular fatty acid trafficking, fatty acid oxidation and ketogenesis and triglyceride 
storage and lipolysis [117, 118].  
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PPAR target genes 
The first identified PPAR direct target was acyl-CoA oxidase, the rate-limiting enzyme 
in peroxisomal long-chain fatty acid oxidation [78]. It catalyzes the first step of b-
oxidation of straight-chain acyl-CoAs which is followed by one of two enzymes carrying 
both enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activity (Ehhadh and 
Hsd17b4) and eventually peroxisomal 30ketoacyl-CoA thiolase (Acca1a and Acca1b) 
[119-128]. All these genes are PPAR targets. Additionally, PPARalso regulates the 
expression of genes involved in fatty acid uptake (Abcd2 and Abcd3), conversion of fatty 
acid to acyl-CoA (Crot), and thioesterases (Acots). In mitochondrial -oxidation, PPAR 
induces genes regulating fatty acid import (Slc25a20, Slc22a5, Cpt1, and Cpt2). 
PPARalso regulates the major enzymes in the β-oxidation pathway, including acyl-
CoA dehydrogenases (Acad), trifunctional enzyme (Hadh), and genes responsible for the 
β-oxidation of unsaturated fatty acid (Dci, Decr) [120-124, 129-134]. In addition, 
synthesis of ketone bodies via mitochondrial HMG-CoA synthase (Hmgcs2) and HMG-
CoA lyase (Hmgcl) is governed by PPAR. PPARalso regulates the expression 
electron transferring flavoprotein and the corresponding dehydrogenase (Etfa, Etfb, Etfdh) 
[122, 124]. Finally, PPAR induces uncoupling proteins Ucp2 and Ucp3, which have 
been proposed to transport nonesterified fatty acid anions out of mitochondrial matrix 
[135-139].  
Cyp4A gene expression is also regulated by PPAR in both mice and humans. Cyp4A 
enzymes belong to the cytochrome P450 monoxygenase superfamily and are in charge of 
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catalyzing microsomal ω-hydroxylation of fatty acids [140, 141]. Using PPAR deficient 
mice, studies demonstrated an almost complete dependence on PPAR for the expression 
of Cyp4a genes (Cyp4a10, Cyp4a12, Cyp4a14 in mice, Cyp4a1, Cyp4a3 in rat, and 
Cyp4a11 in human) [122, 123, 129, 140, 142]. In these experiments, gene expression is 
extremely sensitive to PPAR ligand treatment, suggesting that Cyp4a genes may be 
PPAR downstream targets. The ω-hydroxylation of saturated and unsaturated fatty acids 
may cause the production of high affinity endogenous PPAR ligands (i.e. 
hydroxyeicosatetraenoic acids (HETEs)) and create a positive feedback loop [143]. 
Alternatively, the promotion of ω-oxidation by PPAR has been suggested to accelerate 
the degradation of the PPARα agonist leukotriene B4 as a feedback mechanism to control 
the duration of the inflammatory response [144]. 
While PPAR is best known for its ability to induce fatty acid oxidation, PPAR also 
plays important roles in regulation of lipogenesis. Functional PPREs were identified in 
the promoter of a number of lipogenic genes including Δ6 desaturase (Fads2), malic 
enzyme (Mod1), phosphatidate phosphatase (Lpin2) and Δ9 desaturase (Scd1) [145-148]. 
In contrast to de novo fatty acid synthesis, the synthesis of triglycerides may be directly 
regualted by PPAR. Several genes within these pathways are promoted by PPAR 
activation, including Gpam, Agpat genes, Mogat1, Dgat1, and Lpin2 [122, 124, 134, 149]. 
This may reflect a role of PPAR in neutralizing incoming adipose tissue-derived free 
fatty acids in response to fasting. The activation of PPAR also upregulates fatty acid 
transport proteins including Slc27a1, Slc27a2, Slc27a4, Fabp1,  Fabp2, Fabp3, and Fabp4 
in the liver [122, 124]. 
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There is a large number of evidence from clinical studies showing that fibrates effectively 
lower plasma TG and raise plasma HDL [150-152]. Since fibrates act as synthetic agonist 
for PPAR, PPAR have been indicated to play important roles in the control of 
lipoprotein metabolism. Plasma TG is lowered by PPARpartly due to the reduction in 
VLDL [153]. This effect of PPAR is largely attributed to the induction of genes 
involved in fatty acid oxidation and the reduction in available lipid for VLDL production. 
However, in addition to its role in fatty acid catabolism, PPAR also influences 
intracellular lipid trafficking and metabolism as mentioned earlier, some of which may 
accelerate hepatic lipid importing. On the other hand, PPARalsopositively regulates 
the expression of microsomal triglyceride transfer protein (Mttp). Mttp is an enzyme 
involved in formation of nascent VLDL particle using apoB100 [154]. With positive 
roles in both VLDL uptake and secretion from liver, the activation of PPARaccelerates 
the lipid turnover rate within the body.  
In addition to suppressing VLDL secretion, PPAR agonists are also known to stimulate 
clearance of TG-rich lipoproteins [153]. Lipoprotein lipase (LPL) is attached to the 
capillary endothelium of peripheral tissues such as skeletal muscle and adipose and 
mediates the clearance of TG-rich lipoproteins VLDL and chylomicrons. Expression of 
Lpl in liver is restricted to Kupffer cells [155, 156]. No evidence is available supporting a 
stimulatory effect of PPAR on the expression of LPL in tissues such as heart and 
skeletal muscle, which account for the majority of triglyceride clearance from plasma 
[155, 157]. However, the post-translational regulation influences most for the activity of 
LPL activity. LPL-modulating factors include apolipoprotein C-III (Apoc3), 
apolipoprotein A-V (Apoa5). Angiopoietin-like protein 3 (Angptl3) and Angiopoietin-
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like protein 4 (Angptl4) have also been indicated as LPL-modulators. It is now clear that 
PPAR agonists increase LPL activity by altering the secretion of these proteins. PPAR 
downregulates the expression of LPL inhibitor APOC3 [158]. PPAR increases hepatic 
expression and secretion of APOA5, which is a positive regulator of LPL activity [159]. 
A functional PPRE has been validated in the promoter region of the APOA5 gene, 
confirming APOA5 as a direct PPAR target [160, 161]. PPAR promotes the 
expression of Angptl4 in plasma and liver. Anpgtl4 converts active LPL dimers to 
inactive monomers and therefore inhibits its activity [162]. The PPRE is located to one of 
the introns of the Angptl4 gene [163]. With pharmacological PPAR activation, PPAR 
regulates the aforementioned gene expression and promotes LPL activity and therefore 
stimulates plasma TG clearance. 
Other than TG clearance, activation of PPAR also raises plasma HDL levels in humans.  
This is achieved through promotion of apolipoprotein A-I (Apoa1) and A-II (Apoa2) 
expression [164, 165]. In rodents, however, gene expression of Apoa1 is not promoted by 
PPAR, because of disabling mutations within the PPRE [166]. PPAR activation in 
mouse downregulates Apoa1 mRNA expression and plasma concentrations [166-168].  
1.2.2 Fenofibrate 
Introduction 
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Figure 1.6. Chemical structure of fenofibrate. 
Fenofibrate is a fibric acid derivative and has been available for decades as a treatment 
for dyslipidemia [169]. It is recommended in addition to diet restriction and other non-
pharmacological approaches such as physical exercise for the treatment of severe 
hypertriglyceridemia and mixed hyperlipidemia in patients with statins intolerance. It is 
also prescribed as a secondary or combined therapy to statins in patients with mixed 
hyperlipidemia when TGs and HDL cholesterol are not satisfactorily controlled by statins 
therapy alone [169]. 
Mechanism of action 
Fenofibrate is an orally administered prodrug that is converted to fenofibric acid by 
esterases following absorption, which is its pharmacologically active metabolite [170]. 
The lipid-lowering effects of fenofibrate are mediated through the activation of 
peroxisome proliferator-activated receptor- (PPAR) [171]. Briefly, PPAR 
heterodimerizes with retinoid X receptor (RXR), and binds to specific peroxisome 
proliferator response elements (PPRE), thereby modulating the expression of genes 
involved in lipid metabolism [170-172]. Activation of PPAR results in increased 
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lipolysis and clearance of TG-rich lipoproteins from circulation. Molecular mechanism 
involves the promoted activation of lipoprotein lipase and reduced production of the 
lipoprotein lipase inhibitor ApoCIII from liver [155, 173-175]. Fenofibrate also promotes 
fatty acid -oxidation, which reduces the availability of free fatty acids for TG synthesis 
[155, 173-175]. De novo fatty acid synthesis is also inhibited by fenofibrate through the 
reductions in acetyl-CoA carboxylase and fatty acid synthase activity, which also reduces 
the available fatty acid pool in liver for TG synthesis [175, 176]. Hepatic ApoB and 
VLDL production and secretion are reduced by fenofibrate treatment [175, 176]. 
Fenofibrate increases LDL clearance and reduces small dense LDL levels in plasma [177-
180]. However, larger LDL particles have a high binding affinity for LDL receptors, 
which makes them less susceptible to oxidation [173, 177, 178]. PPAR activation also 
increases the synthesis of ApoAI and ApoAII, which are the major protein components in 
HDL particles [164, 175, 176, 181]. It enhances the expression of ATP-binding cassette 
transporter A1 (ABCA1) and scavenger receptor-B1 (SRB1), which leads to HDL-
mediated cholesterol efflux from macrophages [170, 171, 173, 182, 183]. Fenofibrate 
treatment causes the increase in plasma HDL cholesterol levels [173, 177, 184], which is 
the results of reductions in the activity of cholesteryl ester transfer protein (CETP), the 
key enzyme that mediates the lipid transfer from HDL to VLDL [173, 177].  
Therapeutic efficacy 
The therapeutic efficacy of fenofibrate has been demonstrated in large amounts of clinical 
studies in adults [185-197]. In the FIELD trial, the comparison of fenofibrate 
monotherapy was compared with placebo in patients with type 2 diabetes [185]. Patients 
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generally had no indication for other hypolipidemic therapy although considered to be at 
higher risk of coronary heart disease. They also showed good glycemic control. There 
was 24% relative reduction in nonfatal myocardial infarction in patients on fenofibrate vs 
those on placebo. Fenofibrate also reduced 11% total cardiovascular disease events and 
20% coronary revascularization compared with placebo. Based on a post hoc subgroup 
analysis, fenofibrate treatment exhibited the greatest effects in patients with significant 
baseline hypertriglyceridemia or dyslipidemia. In another two trials, the effects of 
fenofibrate were compared with gemfibrizol with regards to improvement in TG and 
HDL cholesterol [186, 187]. No significant difference was observed between two 
treatment approaches, although total cholesterol and LDL cholesterol was reported to 
drop greater in fenofibrate treated patients. In comparison with statins, fenofibrate 
consistently showed greater improvements in TG and HDL cholesterol levels in patients 
with hypercholesterolemia, while fenofibrate was less effective in reducing total 
cholesterol and LDL cholesterol [188-193]. Compared with niacin, fenofibrate improved 
TG and HDL cholesterol with more significance but less effectively in improving total 
cholesterol and LDL cholesterol in patients with mixed dyslipidemia [194].  In the 
ACCORD Lipid trial, the treatment effects were compared between fenofibrate plus 
simvastatin and placebo plus simvastatin in patients with type 2 diabetes who were at 
higher risk of cardiovascular diseases [195, 196]. No significant difference was observed 
in either primary nor secondary endpoints between the two groups. However, fenofibrate 
plus simvastatin significantly improved the total cholesterol, HDL cholesterol and TG 
levels compared with placebo plus simvastatin. In a trail to evaluate the additive effect of 
fenofibrate to the combination of stain and ezetimibe, fenofibrate further improved lipid 
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profiles in patients with mixed dyslipidemia after 12 week of treatment [197]. Addition of 
fenofibrate significantly further improved HDL cholesterol and TG than statin/ezetimibe 
combined treatment alone [197]. 
1.3 PEROXISOMAL ABC TRANSPORTERS 
1.3.1 PEROXISOMES 
Introduction 
Peroxisomes are subcellular organelles that are present in almost all eukaryotic cells. 
They are characterized by a single layer membrane containing granular matrix and a 
crystalline core [198]. The first reported discovery of these organelles dates back to 
1950s when subcellular particles bound by a single membrane containing matrix and a 
crystalline core were observed in kidney and live cells [199]. The term ‘peroxisome’, 
however, was not proposed until 1960s with the identification of oxidases and catalases 
within these organelles [200]. Early studies on peroxisomes focused on their functions on 
hydrogen peroxide metabolism and were greatly facilitated by the utilization of 3, 3’-
diaminobenzadine (DAB) staining [201]. Later on, peroxisomes were reported to exist in 
a large number in tissues with active lipid metabolism, including liver, intestine, brain 
and adipose [202, 203]. The shape and size of peroxisomes vary in different tissues, with 
the diameter ranging from 0.1um to 0.5um. Peroxisomes tend to be smaller in adipocytes 
and often observed without a crystalline core. Therefore, adipose peroxisomes were 
referred to as ‘microperoxisomes’ [202]. Besides oxidative catalytic functions, 
peroxisomes are actively involved in a variety of metabolic processes, including -
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oxidation of very long chain fatty acids (VLCFA), -oxidation of branched chain fatty 
acids and biosynthesis of ether-phospholipids [204].  
Biogenesis of Peroxisomes 
Peroxisomes are highly dynamic and plastic organelles that readily respond to 
environmental change and metabolic stress. Although the origin of peroxisomes still 
remains controversial, there are currently two alternative theories that describe the 
generation and population of peroxisomes. In a classical model, peroxisomes are 
autonomous and generate from existing peroxisomes [205]. Some peroxisomes exhibit a 
dumbbell shape in fixed tissues, reflecting the ongoing dividing process that was captured 
histologically [206]. Such structures are more often observed in rodent livers after 
peroxisome proliferator treatments, which greatly induce the peroxisome division and 
growth [207].  
In a relatively new model, peroxisomes are described as semiautonomous organelles that 
derive their matrix protein from cytosolic ribosomal synthesis and import their membrane 
proteins and lipid components from the endoplasmic reticulum (ER) [208]. Peroxisomes 
were observed in contact with smooth ER in guinea pig intestine and were suggested to 
arise from local ER regions containing high concentrations of catalases [207, 209]. Using 
fluorescent labeled peptides fused to peroxisomal proteins, it was shown that precursors 
of peroxisomes dissociating from ER in a ‘budding’ pattern [210]. Two preperoxisomal 
vesicles underwent heterotypic fusion and formed a new organelle that continued to 
import matrix proteins from cytosol [210]. 
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The assembly of peroxisomes, especially that of the membrane protein and components 
requires the assistance of a group of proteins called peroxins. The majority of studies on 
peroxisomal biogenesis are done using yeast as a model because of its ease to manipulate 
and proliferate [211]. Over 30 peroxins have been identified in yeast, at least 23 of which 
are essentially required for the peroxisomal biogenesis [212, 213]. There are at least a 
dozen of peroxins conserved in mammals. The peroxisomal membrane and membrane 
protein assembly critically requires at least three proteins, which are Pex3, Pex16, and 
Pex19. As a chaperone protein, Pex19 functions as an import receptor for newly 
synthesized proteins [214]. Pex3 is localized in a preperoxisomal vesicle budding from 
ER and serves as a docking receptor for peroxisomal membrane proteins [215]. Pex16 
assists Pex19 for the recruitment of Pex3 and carried peroxisomal proteins [216]. The 
peroxisomal matrix proteins are imported through a different mechanism. These proteins 
have a sequence of amino acids, called PTS, at carboxyl (PTS1) or amino (PTS2) 
terminus that directs newly translated protein from the cytosolic ribosomes to 
peroxisomes [217, 218] . Pex5 and Pex7 are the import receptors for PTS1-and PTS2-
containing matrix proteins, respectively [219, 220]. They first deliver proteins from 
cytoplasm to docking sites at peroxisomal membrane and then recycle back to the 
cytoplasm [221].  
Fatty Acid Oxidation in Peroxisomes 
Both peroxisomes and mitochondria are sites for fatty acid oxidation in animal cells. 
Although both organelles metabolize fatty acyl-CoAs, their roles are not interchangeable. 
Peroxisomes are the major place for -oxidation of very long chain fatty acids (VLCFA), 
-oxidation of branched chain fatty acids and biosynthesis of ether-phospholipids [204].  
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The overall mechanism of β-oxidation is the same in peroxisomes and mitochondria and 
contains four consecutive enzymatic steps which include dehydration, hydration, 
oxidation and thiolysis. Although the chemical reactions are essentially the same in the 
two organelles, they use different enzymatic machineries to catalyze these reactions. 
Mitochondria use acyl-CoA dehydrogenase to catalyze the first step of β-oxidation and 
generate a molecule of FADH2 whose energy is used to produce two molecules of ATP. 
The peroxisomes, on the other hand, use acyl-CoA oxidase to catalyze the first step and 
produce one molecule of FADH2. However, since peroxisomes don’t have a respiratory 
chain, electrons from FADH2 are directly passed to O2 and creating H2O2. Instead of 
being used to generate ATP, the energy is released as heat. Therefore, fatty acid oxidation 
in peroxisomes is less energy efficient. In addition, the major results of fatty acid 
oxidation in peroxisomes is to shorten very long chain fatty acids rather than complete 
oxidized them [222, 223]. Fatty acids of 26 carbon or more are  oxidized exclusively in 
peroxisomes, while fatty acids with less carbon can be oxidized in both organelles [224]. 
Peroxisomes also transport fatty acyl-CoA in a different pattern than mitochondria. 
Mitochondria utilize a carnitine exchange system to uptake fatty acyl-CoA across 
membrane which consists of carnitine palmitoyl-transferases 1 and 2 (CPT1 and CPT2) 
and carnitine-acylcarnitine translocase (CACT). CPT1 is localized on the outer 
membrane and replaces the CoA with carnitine, generating a fatty acid carnitine, which is 
transferred across the inner membrane to mitochondrial matrix by CACT. CPT2 then 
convert fatty acid carnitine back to fatty acyl-CoA by replacing the carnitine with CoA. 
However, peroxisomes use three ATP binding cassette transporters on the membrane to 
uptake substrates [225].  
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Peroxisomal ABC Transporters 
To transport metabolites across the membrane, peroxisomes need the facilitation of 
different metabolic transporters. One of the transporter families is the ATP-binding 
cassette (ABC) transporter subfamily D which contains four members: 
adrenoleukodystrophy protein (ALDP/ABCD1), ALDP-related protein 
(ALDRP/ABCD2), a peroxisomal membrane protein (PMP70/ABCD3) and PMP70-
related protein (P70R/ABCD4). The first three has been identified as peroxisomal 
transporters while the last was reported to be localized to endoplasmic reticulum (ER) 
[226].  
ABCD1 (D1) is involved in the peroxisomal uptake of a variety of VLCFA-CoA [227, 
228]. Dysfunction of D1 leads to impaired peroxisomal -oxidation and causes the 
human genetic disorder X-linked adrenoleukodystrophy (X-ALD), which is characterized 
by the accumulation of VLCFA in plasma and tissues. Transfection of ABCD1 cDNA 
into X-ALD skin fibroblasts restored the VLCFA oxidation and brought the VLCFA 
content to normal [229, 230]. Besides closely related to fatty acid metabolism, ABCD1 
gene expression was also reported to respond to cholesterol level in human THP-1 cells 
and primary macrophages [231]. In wild-type mice, cholesterol feeding increased the 
plasma cholesterol level while this response was lost in Abcd1 deficient mice [232]. 
Although the mechanism by which cholesterol affects D1 expression has not been 
elucidated, these findings suggest a possible link between D1 function and cellular 
cholesterol metabolism.  
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ABCD2 (D2) shares 66% amino acid identity with D1 and is presumed to have 
overlapping substrate specificity based on complementation studies in yeast [228, 233]. 
Additionally, a ubiquitous promoter-controlled D2 transgene corrected both biochemical 
and neurological phenotypes in D1 deficient mice, indicating that they share overlapping 
functions [234, 235]. Mice lacking D2 are characterized by late-onset cerebellar and 
sensory ataxia with loss of cerebellar Purkinje cells and accumulation of VLCFA in 
dorsal root ganglia cells [236]. D2 deficient mice also showed evidence of oxidative 
stress with spontaneous and premature ceroid deposition in adrenal medulla cells [237], 
reduced rates of VLCFA (C26:0) and PUFA (C24:63) oxidation, as well as altered 
LCFA and VLCFA levels (C20:0, 22:19, 22:63 and 22:56) in the cerebral cortex 
[238]. D1 and D2 appear to cooperate in monounsaturated C26:19 import [239] and 
serum levels of C22:19, a fatty acid associated with disruptions in lipid metabolism in 
rats and other species [240], were elevated in fed and fasting states [238, 241]. The 
absence of D2 sensitized mice to dietary erucic acid, resulting in the rapid onset of 
obesity and insulin resistance [242].  
The expression of D2 is dynamically regulated by several transcription factors, including 
PPAR, sterol regulatory element binding proteins SREBP1a and SERBP1c, retinoid X 
receptor (RXR), thyroid hormone receptor (TR), LXR and TCF4/-catenin [130, 232, 
243-245]. D2 expression levels in liver are near the lower limit of rtPCR and 
immunoblotting detection, but are dramatically up-regulated by PPAR agonists and in 
genetic and high fat feeding obesity models [242, 246]. Although no functional 
peroxisome proliferator response element has been identified in the D2 promoter, the 
expression of D2 is induced by fibrate treatment and is PPARdependent [130]. 
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Prolonged fasting for 48 hours was also shown to increase both hepatic D2 expression 
and the amount of some peroxisomal metabolites (C20:0 and C22:1) in mouse serum 
[238]. Collectively, these data demonstrate a number of key functions for D2 as a lipid 
homeostasis regulator. However, the precise physiological role of D2 in lipid metabolism 
remains largely unknown.  
ABCD3 (D3) is one of the most abundant peroxisomal membrane proteins at least in 
hepatocytes. Overexpression of D3 in CHO cells induced the -oxidation of plamitic acid 
(C16:0) and inhibited the -oxidation of tetracosanoic acid (C24:0), suggesting its role in 
the metabolic transport of long chain and very long chain fatty acids [247]. In Abcd3 
deficient mice, the bile acid precursors, trihydroxycholestanoic acid (THCA) and 
dihydroxycholestanoic acid (DHCA), as well as pristanic acid accumulated in plasma 
[248]. In Abcd3 deficient mouse fibroblast, the -oxidation of phytanic and pristanic acid 
was decreased to 50% of control [248]. These results indicate that D3 is required for the 
transport of LCFA-CoA, THCA-CoA, DHCA-CoA and branched chain acyl-CoA and 
essential for bile acid synthesis.  
 
1.4 PEROXISOMES IN ADIPOSE TISSUES 
More than the major depot for lipid storage as an energy source backup, adipose tissue is 
also an active endocrine organ that secretes various adipokines and other signal 
molecules. Peroxisomes tend to be smaller in adipocytes and are often observed with 
absence of the crystalline core. Therefore, adipose peroxisomes were referred to as 
‘microperoxisomes’ [202]. Nevertheless, microperoxisomes are abundant in adipocytes 
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and are observed in close relationship with lipid droplets. A large number of 
microperoxisomes are present in cultured 3T3-L1 adipocytes and mouse epididymal fat 
[203, 249].  
Brown adipose tissue also harbors a large amount of ‘catalase-positive particles’ and tend 
to increase their number dramatically in response to cold exposure [250]. Later studies 
demonstrated the presence of oxidase in these particles which identified them as 
peroxisomes [251]. During adipocyte differentiation and exposure to low temperature, the 
Pex genes increased in a PGC1 dependent manner, indicating potential roles of 
peroxisomes in brown adipose physiology [252].  
Recently, there has been emerging evidence indicating that peroxisome metabolism is 
critically required for normal adipose function [253, 254]. In Pex7 deficient mice, 
peroxisome biogenesis is impaired due to the failure of peroxisomal protein import [254]. 
These mice lack plasmalogens, the synthesis of which strictly relies on peroxisomal 
metabolism, and had severely reduced adiposity despite similar food intake. The 
phenotype could be rescued by feeding the mice with alkyl-glycerol and restoring 
plasmalogen levels [254]. Presumably, exogenous alkyl-glycerol enters the ether lipid 
synthetic pathway in peroxisomal metabolism and increase the production of 
plasmalogen. However, the exact amount of endogenous ether phospholipids in adipose 
tissue was not reported. Although a direct requirement for peroxisome-derived lipids in 
adipose development was suggested by the authors, it was not confirmed that 
plasmalogen was the signaling molecule. Moreover, it remains to be further determined 
whether adipose dysfunction in Pex7 deficient mice is due to defective PPARγ signaling.  
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In another mouse model in which Pex5 was specifically deleted in adipose using aP2 
promoter, peroxisomes were dysfunctional in white adipose tissue, but intact in liver, 
heart, pancreas, and muscle [253]. Adipose function was impaired resulting in reduced 
lipolysis and increased fat mass. However, other phenotypes were also observed 
including failure of catalase import into peroxisomes in the nervous system, impaired 
shivering thermogenesis, and reduced plasma adrenaline levels, suggesting some adipose 
phenotypes were due to secondary effect or off-target Pex5 deletion.   
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CHAPTER 2: ABCD2 MODIFIES PPAR SIGNALING IN VITRO BUT DOES 
NOT IMPACT RESPONSE TO FENOFIBRATE THERAPY IN A MOUSE 
MODEL OF DIET-INDUCED OBESITY 
 
Introduction 
Fenofibrate has been widely used clinically to treat dyslipidemia. As an agonist of PPAR 
(peroxisome proliferator-activated receptor) , fenofibrate has been shown to 
significantly reduce TG (triglyceride) levels and raise HDL (high density lipoprotein) 
cholesterol levels in plasma [176, 255]. However, the clinical response to fenofibrate 
therapy is highly variable [256]. It has been proposed that response variability may be 
partially due to fenofibrate therapy and genetic factor interactions [257]. Polymorphisms 
at several genes have been reported to interact with the lipid-lowering effects of 
fenofibrate during the postprandial period [258-264]. However, only a limited number of 
genes have been investigated so far, and the effects of other candidate genes, especially 
those that play important roles in lipid metabolism, remain unexplored.  
ABCD2 (D2) is a mammalian peroxisomal ABC transporter thought to facilitate very 
long chain fatty acyl-CoA import into peroxisomes for -oxidation [236, 238, 265]. 
Impaired peroxisome functions lead to very long chain fatty acid (VLCFA) and branched 
chain fatty acid (BCFA) accumulation in plasma and tissues, resulting in severe 
metabolic diseases [266]. X-linked adrenoleukodystrophy is a peroxisomal disorder 
caused by inactivation of the ABCD1 (D1) gene [267]. D2 shares 66% amino acid 
identity with D1 and is presumed to have overlapping substrate specificity based on 
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complementation studies in yeast [228, 233]. Additionally, a ubiquitous promoter-
controlled D2 transgene corrected both biochemical and neurological phenotypes in D1 
deficient mice, indicating that they share overlapping functions [234, 235]. 
D2 protein has been detected in adrenal, brain, kidney, liver, and skeletal muscle, but is 
most abundant in adipose [241]. Mice lacking D2 are characterized by late-onset 
cerebellar and sensory ataxia with loss of cerebellar Purkinje cells and accumulation of 
VLCFA in dorsal root ganglia cells [236]. D2 deficient mice also showed evidence of 
oxidative stress with spontaneous and premature ceroid deposition in adrenal medulla 
cells [237], reduced rates of VLCFA (C26:0) and PUFA (C24:63) oxidation, as well as 
altered LCFA and VLCFA levels (C20:0, 22:19, 22:63 and 22:56) in the cerebral 
cortex [238]. D1 and D2 appear to cooperate in monounsaturated C26:19 import [239] 
and serum levels of C22:19, a fatty acid associated with disruptions in lipid metabolism 
in rats and other species [240], were elevated in fed and fasting states [238, 241]. The 
absence of D2 sensitized mice to dietary erucic acid, resulting in the rapid onset of 
obesity and insulin resistance [242].  
The expression of D2 is dynamically regulated by several transcription factors, including 
PPAR, sterol regulatory element binding proteins SREBP1a and SERBP1c, retinoid X 
receptor (RXR), thyroid hormone receptor (TR), LXR and TCF4/-catenin [130, 232, 
243-245]. D2 expression levels in liver are near the lower limit of rtPCR and 
immunoblotting detection, but are dramatically up-regulated by PPAR agonists and in 
genetic and high fat feeding obesity models [242, 246]. Although no functional 
peroxisome proliferator response element has been identified in the D2 promoter, the 
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expression of D2 is induced by fibrate treatment and is PPARdependent [130]. 
Prolonged fasting for 48 hours was also shown to increase both hepatic D2 expression 
and the amount of some peroxisomal metabolites (C20:0 and C22:1) in mouse serum 
[238]. Collectively, these data demonstrate a number of key functions for D2 as a lipid 
homeostasis regulator. However, the precise physiological role of D2 in lipid metabolism 
remains largely unknown.  
Our initial studies revealed that absence of D2 altered the genomic response to 
fenofibrate treatment in mouse liver, and confirmed that D2 protein levels altered 
responses to fibrate treatment in vitro. This prompted us to propose that D2 may play a 
role in the regulation of PPAR signaling and response to fenofibrate therapy. We next 
tested the hypothesis that D2 would alter the effect of fibrate in a model of diet-induced 
obesity. Fibrates decreased weight gain, adiposity, hyperlipidemia and insulin resistance, 
but these effects were not altered by the D2 genotype.  
 
Materials and Methods 
Analysis of hepatic gene expression and sample preparation 
Animals 
Age-matched (3 month, n=6) wild-type (WT) and Abcd2 (D2) knock-out (KO) mice on 
the C57Bl/6J background were gavaged (200 µL/day) with fenofibrate (100 mg/kg/day) 
dispersed in water containing 3% gum arabic for 14 days. Control mice were gavaged 
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with vehicle alone (3% gum arabic). Livers were dissected from the mice and total RNA 
was extracted using RNeasy Kit (Qiagen).  
Microarray 
A cDNA microarray was manufactured at IGBMC (Institut de Génétique et de Biologie 
Moléculaire et Cellulaire). The array consisted of 20,736 mouse cDNA clones 
representing approximately 15,000 Unigene clusters. The clone selection, cDNA 
amplification, spotting, and labelling in two colors (dUTP-Cy3 and dUTP-Cy5) has 
previously been described [268]. Arrays were scanned using ScanArray 4000 (Packard 
Biochips, Billerica, MA, USA) and images quantified using Imagene 5.0 (BioDiscovery 
Microarray Bioinformatics Software, Marina Del Rey, CA, USA). Detailed information 
is available on the IGBMC microarray web site (http://www-microarrays.u-strasbg.fr). 
The microarray experiment has been deposited in the Array Express Database under 
accession number E-MTAB-2006. 
Hybridization and data processing 
All samples were hybridized in duplicate and analyzed using dye swap to avoid label 
specific bias. Pre-processing of raw data and statistical analyses were performed using 
Bioconductor packages in R programming environment [269]. For mouse custom cDNA 
arrays, background correction was performed using the "normexp" method implemented 
in the Bioconductor LIMMA package to adjust local median background estimates [270, 
271]. Background-corrected intensity data were normalized using the Print-tip loess 
method to remove the bias within each array and the A-values quantile normalization 
(Aquantile) to remove the bias between arrays. 
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Functional enrichment analysis 
To evaluate which pathways or functional categories were enriched in differentially 
expressed genes we computed both the Gene set enrichment analysis (G) and 
Hypergeometric distribution function (H). We used P<0.05 as the cut-off point to 
determine whether the metabolic and cell signalling pathways extracted from The Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/) [272] 
were significantly enriched. GeneSetTest function from LIMMA package tests whether a 
set of genes is enriched for differential expression. Its principle is the same as for Gene 
Set Enrichment Analysis introduced by [273], but the statistical tests used are different. It 
is based on a set of probe-wise t-statistics arising for microarray analysis. We have 
computed three different tests: i) up-regulated genes, with positive t-statistics as indicated 
by red spots, ii) down-regulated genes, with negative t-test statistics as indicated by green 
spots, and iii) genes differentially expressed regardless of the direction as indicated by 
black spots. The sizes of spots are scaled positively with the probability values in a semi-
quantitative pattern. We used the “phyper” hypergeometric distribution function from 
stats package to determine enriched KEGG pathways in the subset of genes differentially 
expressed at P<0.05. 
Impact of D2 on fibrate response in vitro 
Generation of D2 deficient 3T3-L1 cell line 
3T3-L1 cells were propagated as fibroblasts in sub-confluent cultures in DMEM/F12 
supplemented with antibiotics and 10% newborn calf serum. One day post-confluence, 
cells were infected with lentiviral particle expressing short hairpin RNA directed against 
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D2 (sequence: 5ʹ-
CCGGCCTCGGACTTTCATCATCAAACTCGAGTTTGATGATGAAAGTCCGAGGT
TTTTG-3ʹ, Sigma MISSION® shRNA Lentiviral Transduction Particles 
TRCN0000105346) and a control shRNA in the presence of hexadimethrine bromide 
(polybrene, 8 ug/ml). Cell-viral particle mixtures were incubated in 37°C overnight. 
Medium was replaced with DMEM/F12 containing antibiotics and 10% newborn calf 
serum. 2ug/ml puromycin was added to select successfully transduced cells. Medium was 
replaced every three days until resistant clones could be identified. Several puromycin-
resistant colonies were selected by limiting dilution, expanded separately in medium 
containing reduced amount of puromycin (1 ug/ml), and frozen in liquid nitrogen. Cell 
lysates of each expanded colony were prepared and subjected to immunoblot analysis to 
confirm knockdown of D2.  
Adipocyte differentiation and fenofibrate treatment 
D2 deficient 3T3-L1 and control cells were propagated as fibroblasts in sub-confluent 
cultures in DMEM/F12 supplemented with antibiotics and 10% newborn calf serum. Two 
days post-confluence (Day 2), cells were treated with a 1.7 µM insulin, 0.5 µM 
dexamethasone, 0.5 mM isobutylmethylxanthine, and 1 µM rosiglitizone in DMEM/F12 
supplemented with 10% fetal calf serum and antibiotics for 48 hours to promote 
differentiation to adipocytes as previously described [241].  Thereafter, cells were 
cultured in DMEM/F12 supplemented with 10% fetal calf serum. Four days post-
confluence (Day 4), the medium was replaced with DMEM/F12 supplemented with 
antibiotics, 10% fetal calf serum, and 1 ug/ml insulin. Fresh medium was replaced every 
two days. 3T3-L1 adipocytes were analyzed between 8-12 days post-confluence. Eight 
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days post-confluence (Day 8), adipocytes were treated with carrier (DMSO) or 
fenofibrate (500mM) for 16 hours. Cells were washed with PBS (4°C) and total RNA 
was extracted using RNeasy kit (Qiagen, Valencia, CA).   
Protein sample preparation and immunoblotting 
Cell lysates were prepared by incubating the cells in triton lysis buffer (80 mM NaCl, 50 
mM Tris, 2 mM CaCl2, 1% Triton, pH 8.0) at 4°C for 30 min, scraped off the dish, and 
homogenized with polytron homogenizer. Samples were added with protein sample 
buffer (30mM Tris base, 10mM EDTA, pH 6.8, 3% SDS, 20% glycerol, and 0.00625% 
bromphenol blue) to achieve uniform concentrations. -mercaptoethanol was added to a 
final concentration of 1.2% (v/v). Samples were heated to 95 °C for 5 min before loading. 
Proteins were size-fractionated on 10% SDS-polyacrylamide gels and transferred to 
nitrocellulose membranes. Membranes were incubated in buffer A (20 mM Tris, 137mM 
NaCl, 0.2% Tween 20 and 5% non-fat milk, pH 7.6) for 30 min at room temperature. 
Anti-ABCD2 antibody [241] was diluted in buffer A and incubated with membranes for 
60 min at room temperature. Membranes were washed 3 times for 5 min in buffer B (20 
mM Tris, 137mM NaCl and 0.2% Tween 20, pH 7.6). Horseradish peroxidase-conjugated 
goat anti-rabbit IgG were diluted in buffer B and incubated with membranes for 30 min at 
room temperature. Membranes were washed 3 times for 5 min in buffer B and visualized 
by enhanced chemiluminescence (SuperSignal West Pico, Thermo Scientific).  
Quantitative real-time PCR 
Total RNA was reverse transcribed using SuperScriptTM First Strand Synthesis system 
(Invitrogen). Quantitative RT-PCR was performed on an Applied Biosystems 7900HT 
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sequence detection system. Standard reaction volume was 30 ul containing 1X SYBR 
Green PCR master mix (Applied Biosystems), 1 ul of cDNA template, and 150 nM 
concentrations of each oligonucleotide. Initial steps of RT-PCR were 10 min at 95°C. 
Cycles (n=40) consisted of a 15-s melt at 95°C followed by a 1-min annealing/extension 
at 60°C. All reactions were performed in triplicate. Means of the differences in threshold 
cycle (CT) values from cyclophilin and their S.D. were calculated for each treatment 
group (CT). The relative abundance of each transcript within treatment groups was 
determined by subtracting the control group mean difference from the remaining 
treatment groups (CT) and calculated according to the expression 2
-CT
. The S.D. of 
the difference between control and each treatment group was calculated as the square root 
of the sums of squares for the S.D. of the CT means. 
 
Impact of D2 on fibrate response in vivo 
At 8 weeks of age, Abcd2 knock-out (KO) and wild-type (WT) male mice were provided 
free access to a high fat diet (control, 60% kCal, Research Diets Inc., New Brunswick, NJ) 
or the same diet formulated with fenofibrate (Fibrate, 60% kCal plus 0.05% w/w 
fenofibrate, Cayman Chemical 10005368). Mice were housed in a 10 hour dark/14 hour 
light cycle. Every week, mice were weighed and food was replaced.  Fasting blood 
glucose levels and body composition (analyzed by MRI, EchoMRI) were measured at the 
initiation (8 weeks of age) and every 4 weeks of the study.  A glucose tolerance test was 
conducted at the mid-point (8 weeks on diet) and the end (16 weeks on diet) of the study.  
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At 17 weeks, a subgroup of mice was placed in the metabolic cages to record metabolic 
parameters. Each mouse was housed separately and provided with free access to diet and 
water. Mice were allowed to acclimatize for 48 hours. Metabolic data were collected for 
the next 72 hours. Air flow rate (Flow, l/ml), oxygen percentage (dO2, %), carbon dioxide 
percentage (dCO2, %), food and water consumption and locomotor activity were 
measured. Mean values of energy expenditure (H) in the active (dark), resting (light) 
phase, and whole day average were calculated for each mouse. Since the data displayed 
the same pattern for both active and resting phases, we only show the whole day average 
data in this paper.  
Blood samples of these mice were taken using heparinized capillary tubes before and 0.5, 
1, 2, and 3 hours after tail vein injection of 650mg/kg body weight of Triton WR-1339 
(Sigma). Total plasma triglyceride (TG) concentrations of all time points were 
determined and TG secretion rates were calculated using linear regression analysis. 
At 16 weeks, mice were anesthetized with ketamine/xylazine (9/1, w/w) for tissue 
collection.  Tissues were snap-frozen in liquid nitrogen, embedded in Tissue-Tek O.C.T, 
formalin-fixed (10% in PBS), and stored at -80°C until subsequent analysis.  All animal 
procedures were performed with the approval of the Institutional Animal Care and Use 
Committee. 
Statistical Analysis of Data 
Data were analyzed by two-way ANOVA and presented as mean with standard error of 
the mean. Bonferroni post-hoc tests were employed where indicated. All statistical 
analyses were conducted using GraphPad Prism statistical analysis software. 
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Impact of D2 polymorphisms on fibrate responses in human subjects 
Study Population 
The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study, described in 
detail in previous publications [274, 275], was designed to identify genetic markers 
associated with response to fenofibrate therapy in a population of related metabolically 
healthy individuals of European American ancestry. Participants were asked to 
discontinue use of lipid-lowering medications, fast for at least 8 hours, and abstain from 
alcohol prior to study visits. Circulating plasma lipids were measured at baseline and 
after three weeks of daily treatment with 160 mg of micronized fenofibrate. Genotype 
information was collected on 906,600 single nucleotide polymorphisms (SNPs) using the 
Affymetrix Genome-Wide Human 6.0 array and Human Genome Build 36 was used as 
the reference to impute untyped SNPs. After imputation and quality control, a hybrid set 
of 2,543,887 SNPs was created, with complete genotype and covariate information 
available on 861 participants. 
SNP Selection 
Of the three ABCD2 variants previously implicated in affecting gene expression in 
humans [276], the GOLDN data set had genotyped variants that were in perfect linkage 
disequilibrium (R2=1) with two of them, rs7309234 and rs11172592, used as proxies for 
rs4285917 and rs4284427, respectively. The third SNP, rs10783969, was neither typed 
nor in linkage disequilibrium with any of the GOLDN variants and was excluded from 
the analysis. 
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Statistical Analysis of SNP data 
Linear mixed models were used to assess the association of each ABCD2 variant with the 
fenofibrate-induced change in plasma triglycerides, defined as area under the curve 
calculated using the trapezoidal rule. The models were adjusted for age, sex, and study 
site as fixed effects, and pedigree as a random effect. Sensitivity analyses were conducted 
using the alternative phenotype definition of log-transformed plasma triglyceride 
concentration ratios comparing post- to pre-fenofibrate treatment levels. 
Results 
Identification of ABCD2-regulated pathways with and without fenofibrate treatment 
To evaluate the influence of D2 on genomic responses to fibrate treatment, age-matched 
WT and D2 KO mice (n=6) were administered fenofibrate for 14 days. Total RNA was 
extracted from liver and subjected to microarray analysis. To determine which pathways 
or functional categories were enriched among differentially expressed genes, we 
computed both the Gene Set Enrichment analysis (G) and Hypergeometric distribution 
function (H) (Fig. 2.1). Red indicates significance with a preponderance for up-regulated 
genes within the pathway or gene cluster. Green indicates significant down-regulation. 
Black spots indicate significance within the cluster, but without overall up or down trend. 
Open circles indicate no significant differences. The size of the symbols is scaled to the 
magnitude of the P-value. The influence of genotype alone was assessed by comparing 
WT and KO mice without fenofibrate treatment (WT vs. KO, -/- fenofibrate). The effect 
of fibrate treatment was determined by comparing WT mice with or without fibrate (WT 
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vs. WT, -/+ fenofibrate). The interaction between genotype and treatment was evaluated 
by comparing WT and KO mice treated with fenofibrate (WT vs. KO +/+ fenofibrate).  
            
Figure 2.1. Dysregulated pathways in liver samples of KO mice with (+) or without 
(-) fenofibrate treatment.  Biosynthesis of the unsaturated fatty acids pathway is the 
most affected pathway in KO mice with or without fenofibrate. Significant KEGG 
pathways were identified by using the statistics GSEA (G) and Hypergeometric 
distribution function (H). Black spots represent dysregulated pathway when probability 
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value P<0.05, according to the H test that detects change,s but does not inform about their 
up or down direction. Red and green spots represent up- and down- regulated pathway 
expression based on G test when probability value is P<0.05. Black spots in G test 
column indicate significantly dysregulated pathway but without up- or down- trend. Spot 
size scales with the probability value. 
In the absence of fibrate, most pathways were either not affected or only modestly 
influenced by the loss of D2 (WT vs. KO, -/-) in both G and H tests. Fibrate treatment in 
WT mice resulted in altered gene expression in a collection of pathways, including fatty 
acid metabolism, PPAR signaling and biosynthesis of polyunsaturated fatty acids (WT vs. 
WT, -/+). The PPAR signaling pathway was the most significantly influenced by 
fenofibrate as indicated by the size of spots denoting significance in both statistical tests, 
p < 3.27E-21 (Supplemental Table 1). Notably, the PPAR signaling pathway was altered 
in KO mice under basal conditions (without fenofibrate), as shown in G (WT vs. KO, -/-, 
P<0.0009; Supplemental Table 1). With fibrate treatment, the change of gene expression 
in KO mice was still maintained; although the pattern of dysregulation was different (WT 
vs. KO +/+, P<0.001, Supplemental Table 1). This observation indicates that loss of D2 
not only influenced PPAR signaling itself, but also modulated the genomic response to 
fibrates.  Similar results were observed for biosynthesis of polyunsaturated fatty acids 
(Supplemental Table 1).  Alterations in selected in the biosynthesis of PUFAs pathway 
were confirmed by rtPCR (Fig. 2).  
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Figure 2.2. D2 modulates fenofibrate effects on hepatic fatty acid biosynthesis. 
Relative mRNA abundance for fatty acid elongases and desaturases as determined by 
rtPCR. Data were analyzed by two-way ANOVA with genotype and treatment as factors. 
# over lines terminating in horizontal bars indicates significant genotype by treatment 
interaction. * over lines terminating in horizontal bars indicates an overall effect of 
fibrate treatment. * over bars terminating in vertical lines indicates effect of genotype 
within treatment. Bonferonni post-hoc tests were conducted within treatment. # P<0.05, 
## P<0.01, ### P<0.005, #### P<0.001. * P< 0.05, ** P<0.01, *** P<0.005, **** 
P<0.001. 
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Cellular response to fenofibrate treatment is dependent on ABCD2 in 3T3-L1 cells 
Based on alterations in gene expression in mice, we hypothesized that the lack of ABCD2 
may impact PPAR signaling and responses to fibrate treatment.  First, we evaluated the 
influence of D2 on these responses in vitro.  We selected NIH3T3-L1 adipocytes because 
they are the only cell line known to express D2 at high levels and respond to fibrate 
treatment [241, 277].  
We developed a stable clone harboring a shRNA directed against D2 to repress 
expression. Parent 3T3-L1 cells, stable clones with D2 shRNA and control shRNA were 
differentiated to adipocytes. Levels of D2 were confirmed by immunoblotting. Fat from 
WT and KO mice were used as positive (+) and negative (-) controls (Fig. 2.3A). Our D2 
antibody cross reacts with a protein with similar size to D2 in a number of tissues and in 
3T3-L1 adipocytes, but this protein is absent in fat [241]. Total RNAs of shD2 and 
control cells were extracted and analyzed by quantitative real-time PCR to determine the 
expression levels of PPAR family members. Interestingly, the lack of D2 specifically 
suppressed the expression of PPAR, but the other two members of PPAR family,  and 
 were unchanged (Fig. 2.3B).  
Control and shD2 cells were differentiated to adipocytes and treated overnight with either 
carrier or fenofibrate. Expression of PPAR and its target genes were determined using 
real-time PCR (Fig. 2.3C). The mRNA levels of PPAR, CPT1 (carnitine 
palmitoyltransferase 1), UCP2 (uncoupling protein 2) and UCP3 were significantly 
increased in response to fenofibrate treatment in control cells, but the elevation of gene 
expression was blunted in the shD2 cells. Conversely, fenofibrate treatment decreased the 
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expression levels of SCD1 (stearoyl-CoA desaturase 1), SCP2 (sterol carrier protein 2), 
PPAR and ChREBP (carbohydrate-responsive element-binding protein) in control cells, 
but that effect was not influenced by the loss of D2. This suggests D2 modulates genomic 
response to fibrate by influencing the expression of some, but not all the genes in the 
PPAR signaling pathway.  
 
Figure 2.3.  D2 modulates PPAR and fibrate responses in 3T3-L1 adipocytes.  (A) 
3T3-L1 cells and two stable subclones infected with lentiviral particles expressing short 
hairpin RNAs directed against D2 (shD2) or a control shRNA (Control) were 
differentiated into adipocytes that express endogenous D2.  Cell lysates were analyzed 
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for D2 expression by immunoblotting.  Membrane preparations from epididymal fat 
dissected from KO and WT mice were used as negative and positive controls.  NSB 
indicates non-specific band in 3T3-L1 cells.  (B) Expression levels of PPAR family 
members were determined in control and 3T3-L1 adipocytes by rtPCR.  Data were 
analyzed by unpaired t-test  (n=3 independent wells) (C) Control and shD2 3T3-L1 
adipocytes  were treated with fenofibrate (500 mM) or Carrier (DMSO) for 16 hr.  Gene 
expression was determined by rtPCR.  Data were analyzed by two-way ANOVA # over 
lines indicate a detection of a significant interaction at P<0.01.  Bonferonni post-hoc tests 
were conducted within treatment. * P< 0.05, ** P<0.01, *** P<0.001. 
Triglyceride secretion from liver is accelerated by loss of ABCD2 
Fibrate therapy has been shown to successfully oppose diet-induced obesity in mice [278]. 
To investigate the impact of D2 on fibrate response in vivo, we challenged KO and WT 
mice with high fat diet (control, 60% kcal) or the same diet formulated with 0.05% (w/w) 
fenofibrate (Fibrate) for 16 weeks starting at 8 weeks of age. No significant differences in 
body weight, body composition, insulin sensitivity, or other measures of lipid metabolism 
between genotypes were observed at 8 weeks. After high fat diet feeding, both KO and 
WT mice in untreated (control) group developed obesity and hyperglycemia with 
elevated body weight, fat mass percentage, and blood glucose levels (Fig. 2.4). 
Fenofibrate treatment mitigated the increase in body weight and adiposity, but these 
effects were not influenced by loss of D2 (Fig. 2.4A, 4B). Blood glucose levels were 
measured at the initiation (0 weeks on diet), midpoint (8 weeks on diet), and end of the 
study (16 weeks on diet) (Fig. 2.4C). Control KO mice tended to have higher blood 
glucose levels compared to their WT littermates at 8 and 16 weeks of age. However, the 
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difference between genotypes was lost in fibrate treated animals whose blood glucose 
levels were normalized. A glucose tolerance test was done at the endpoint of the study 
(Fig. 2.4D). Glucose tolerance was compromised by the absence of D2. Fibrate lowered 
blood glucose and improved glucose tolerance, but this effect was not altered by the 
absence of D2. 
 
Figure 2.4. Measurement of physiological parameters. Body weights (A) were 
recorded for wild-type mice on high fat diet (WT Control, n=12) and high fat diet 
containing 0.05% fenofibrate (WT Fibrate, n=17), and D2 knock-out mice on high fat 
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diet (KO Control, n=8) and high fat diet containing 0.05% fenofibrate (KO Fibrate, n=17). 
Fat mass percentage (B) of these mice were measured by MRI every four weeks 
(mean±SEM, n=8~17). Blood glucose concentrations (C) were measured every four 
weeks (mean±SEM, n=8~17). Glucose tolerance tests (D) were performed by 
intraperitoneal injection of glucose (1 g/kg) and measurement of blood glucose 
concentration (mean±SEM, n=8~17). AUC for the GTT measurement was also listed 
within panel (D). Statistical comparison was made between two treatment groups using 
two-way ANOVA (mean±SEM, n=8~17, P*<0.05, P****<0.0001). Statistical 
comparison between genotypes within each group was made using Student’s t-test 
(mean±SEM, n=8~17, P**<0.01). 
We analyzed plasma and hepatic lipids from both WT and KO mice with and without 
fenofibrate treatment (Fig. 2.5A-D). Neither genotype nor fibrate treatment altered 
plasma or hepatic cholesterol (Fig. 2.5A and B). Fenofibrate reduced the triglyceride 
levels of plasma and liver, but neither of these effects was altered by the absence of D2 
(Fig. 2.5C and D). KO mice exhibited significantly higher triglyceride secretion rates 
than their WT littermates in both control (WT, 243.0 ± 33.49 mg/dl/hr; KO, 337.7 ± 
27.86 mg/dl/hr) and fibrate (WT, 175.8 ± 17.24 mg/dl/hr; KO, 285.8 ± 21.56 mg/dl/hr) 
groups (Fig. 2.5E and F). However, there was no significant interaction between the 
genotype and the fibrate treatment. This observation suggests that although the static 
plasma triglyceride level was not affected, secretion rate of triglyceride from liver was 
accelerated by loss of D2 with and without fibrate treatment.  
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Figure 2.5. Lipid lowering effect of fibrates dependent on ABCD2. Total cholesterol 
and triglyceride concentrations in plasma (A and C respectively, mean±SEM, n=4~17) 
and liver (B and D respectively, mean±SEM, n=4~5) were measured. Statistical analysis 
was done using two-way ANOVA (P*<0.05, P**<0.01). Triglyceride secretion rates of 
control and fibrate treatment were determined using linear regression analysis (n=3~6). 
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The TG secretion rate was calculated as the slope and the significance of difference 
between two genotypes was demonstrated as P-value. 
We placed a subgroup of mice in the metabolic cages by the end of the experiment. 
Fenofibrate treatment suppressed food intake and promoted energy expenditure, but these 
effects were almost equal for both genotypes (Fig. 2.6). 
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Figure 2.6. Metabolic parameters. Accumulative food consumption (A) and locomotor 
activity (C) of a subgroup of mice were recorded during 72 hour stay in metabolic cages. 
Energy expenditure (B) was calculated based on recorded oxygen and carbon dioxide 
flow. Statistical comparison between fibrate treatment and control groups was made 
using two-way ANOVA (mean±SEM, n=3~6, P**<0.01, P****<0.0001). Significance of 
difference between two genotypes within each group was analyzed using Student’s t-test 
(mean±SEM, n=3~6, P*<0.05). 
Single nucleotide polymorphisms in ABCD2 do not associate with hypolipidemic effects 
of fenofibrate 
Efficacy of fibrate treatment for dyslipidemia in human subjects is highly variable 
between individual patients [256]. To evaluate the association of single nucleotide 
polymorphisms in ABCD2 to fenofibrate treatment efficacy, we analyzed the data from 
the GOLDN study in a population of related metabolically healthy individuals of 
European American ancestry (Table 1). Three SNPs in ABCD2 are associated with 
alterations in expression levels of D2, suggesting they may alter D2 activity in human 
subjects [276]. Two variants genotyped in GOLDN data set analysis, rs7309234 and 
rs11172592, were selected and used as proxies for corresponding D2 variants, rs4285917 
and rs4284427, as each is in linkage disequilibrium with these expression-associated 
SNPs, respectively. Neither variant was associated with responses to fibrate among 
GOLDN participants, suggesting D2 expression is unlikely to alter fibrate responses in 
human subjects. 
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Table 2.1. Association of ABCD2 variants with fenofibrate effects. Linear mixed 
models were used to assess the association of two ABCD2 variants, rs7309234 and 
rs11172592, with the fenofibrate-induced change in plasma triglycerides based on the 
data from the GOLDN study in a population of related metabolically healthy individuals 
of European American ancestry. 
SNP Beta S.E. P-value 
rs7309234 0.009792360 0.0183794364 0.5943369 
rs11172592 0.010279890 0.0084339715 0.4983299 
 
 
Discussion 
The major finding of this study is that D2 modulates PPAR signaling and genomic 
response to fibrate treatment in vitro and in vivo. However, the absence of D2 did not 
alter the impact of fibrate in a mouse model of diet-induced obesity. Although not a 
comprehensive assessment, SNPs associated with altered D2 expression levels were not 
associated with responses to fibrate therapy in human subjects. D2 has long been known 
as a PPAR target gene that is upregulated in response to fenofibrate. To the best of our 
knowledge, this is the first report that demonstrates D2 reciprocally regulates 
PPARsignaling
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A number of gene clusters are differentially affected by fibrate in the presence or absence 
of D2. We verified differential expression of selected genes in the PUFA synthesis cluster 
by rtPCR in mouse liver.  Other clusters affected include pathways associated with lipid, 
bile acid, and steroid metabolism, but have yet to be confirmed by secondary approaches.  
In the present study, we elected to focus on PPAR signaling due to the use of PPAR 
agonists as lipid modifying agents and the variability in response to fibrate treatment.   
In 3T3-L1 cells, suppression of D2 reduced PPAR mRNA levels as well as the 
upregulation of several PPAR target genes in response to fibrate treatment.  
Interestingly, the repression of selected genes by fibrates was unaffected.  This effect 
indicates that D2 selectively modulates fibrate responses and, perhaps PPAR signaling.  
The molecular mechanism responsible for differential effects is unknown, but is likely 
related to D2-dependent peroxisomal metabolism of fatty acids, a source of PPAR 
ligands.  Alternatively, these differences may be due to effects of fenofibrate that are 
independent of PPAR.      
In the absence of fibrates, D2 deficiency resulted in a modest, but significant increase in 
fasting glucose at the midpoint and end of the study, as well as reduced glucose tolerance.  
This is inconsistent with our previously published work in which differences in glycemic 
control were not observed in D2 deficient mice following high fat feeding or when 
crossed onto the ob/ob background [242].  However it should be noted that the previous 
study utilized a 45% kCal high fat diet as opposed to the 60% kCal diet.  Other 
phenotypes, such as weight gain and body composition, were as previously reported. 
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The absence of D2 also reduced TG secretion rates in both the presence and absence of 
fibrate treatment.  In the absence of D2, TG secretion rates in fibrate treated mice are 
indistinguishable from untreated WT mice.  However, this difference was insufficient to 
affect fasting TG levels. MTTP (microsomal triglyceride transfer protein) is known to 
regulate the TG secretion in mice [279], but its mRNA levels were not influenced by loss 
of D2 irrespective of fibrate treatment (data not shown). LPL (lipoprotein lipase) mRNA 
was elevated in the brown adipose tissue in KO mice compared to WT littermates on high 
fat feeding (data not shown). LPL is an enzyme known to hydrolyze triglyceride in 
lipoprotein to release free fatty acid for uptake into peripheral tissues for metabolism 
[280]. Given the role of LPL in TG clearance, the increased LPL expression in the face of 
elevated TG secretion may account for the absence of differences in steady-state plasma 
TGs. 
A number of genetic and environmental factors influence plasma TGs and responses to 
lipid lowering drugs.  We took advantage of an ongoing effort to identify genetic variants 
that influence responses to fibrate therapy to determine if polymorphisms in the ABCD2 
gene might be associated with such differences.  Neither of the two proxy SNPs analyzed 
were statistically significant, suggesting that variants in ABCD2 and alterations in D2 
levels are unlikely to contribute to differences in response to fibrate therapy. However, it 
should be noted that the effects of these SNPs on D2 activity have not been formally 
characterized. Additional studies are needed to fully elucidate the effect of D2 on TG 
metabolism and responses to fibrate therapy.  
Copyright 
@
 Xiaoxi Liu 2014 
60 
 
CHAPTER 3. ABCD2 IDENTIFIES A UNIUE PEROXISOME-LIKE 
SUBCELLULAR ORGANELLE IN MOUSE ADIPOSE TISSUE 
 
Introduction 
Peroxisomes were initially identified in kidney and liver cells as a subcellular organelle 
characterized by a single membrane containing a granular matrix and a crystalline core 
[199]. These dynamic organelles have since been shown to be present in virtually all 
mammalian tissues and cells including adipocytes [203, 204, 281]. Besides the removal 
of reactive oxygen species, peroxisomes are also metabolically involved in the -
oxidation of very long chain fatty acids, -oxidation of branched chain fatty acids and 
biosynthesis of ether-phospholipids [204]. 
Peroxisomes in adipose tissues are often referred to as ‘microperoxisomes’, because they 
are generally smaller in size and lack a crystalline core [202]. Microperoxisomes 
dramatically increase in number during differentiation of cultured 3T3-L1 adipocytes and 
were found to be in the vicinity of lipid droplets [203]. Recently, there has been emerging 
evidence indicating that peroxisome metabolism is critically required for normal adipose 
function [253, 254]. In Pex7 deficient mice, peroxisome biogenesis is impaired due to the 
failure of peroxisomal protein import [254]. These mice lack plasmalogens, the synthesis 
of which strictly relies on peroxisomal metabolism, and had severely reduced adiposity 
despite similar food intake. In another mouse model in which Pex5 was specifically 
deleted in adipose using aP2 promoter, peroxisomes were dysfunctional in white adipose 
tissue but intact in liver, heart, pancreas and muscle [253]. Adipose function was 
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impaired resulting in reduced lipolysis and increased fat mass. However, other 
phenotypes were also observed including failure of catalase import into peroxisomes in 
the nervous system, impaired shivering thermogenesis and reduced plasma adrenaline 
levels, suggesting some adipose phenotypes were due to secondary effect or off-target 
Pex5 deletion.   
ABCD2 has been proposed as a peroxisomal ABC transporter that promotes the transport 
of very long chain fatty acyl-CoA into peroxisomes for -oxidation [248]. The D2 protein 
is expressed in brain, skeletal muscle, lung, liver and testis, but is most abundant in 
adipose tissues in mice and highly expressed in cultured 3T3-L1 adipocytes [241]. The 
mRNA levels of D2 in mouse white adipose tissue respond to fasting and refeeding and 
correspond to SREBP1c-stimulated gene expression [282]. D2 deficient adipose tissue 
showed an increase in the abundance of 20:1 and 22:1 fatty acids. When D2 deficient 
mice were challenged with dietary erucic acid (C20:1), they exhibited rapid onset of 
obesity, hepatic steatosis and insulin resistance [283]. While these data support a key role 
for D2 in lipid metabolism, the function of D2 in adipose and its relationship to adipose 
peroxisome metabolism remains unclear. 
To determine the subcellular localization of D2 and its relationship to adipose 
peroxisomes, we isolated D2-containing organelles from mouse adipose tissue using two 
independent approaches. Our data indicates that the D2-compartment lacks some of the 
well-known peroxisomal proteins such as catalase and PEX19, but possesses other 
peroxisomal enzymes. These results suggest an association of this organelle with 
mitochondria and ER. The most strongly-associated protein with D2 is leucine rich repeat 
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containing protein 59 (LRRC59), a poorly characterized protein implicated in 
intracellular trafficking of FGF1 [284].  
Materials and methods 
Animals 
Age-matched (3 month, n=4) wild-type (WT) and Abcd2 (D2) knock-out (KO) mice on 
the C57Bl/6J background were provided with free access to water and standard chow diet. 
Mice were housed in a 10 hour dark/14 hour light cycle.  
Immunofluorescence microscopy 
Mice were perfused with 10ml 1% fresh paraformaldehyde in phosphate buffered saline 
(PBS) by direct injection into the left ventricle. Epididymal fat pads were dissected and 
placed into 1% paraformaldehyde for 10min at room temperature. The tissue was washed 
in three changes of PBS for 10min each and cut into desired number of samples with 
approximately finger-nail size. Each sample was put into a 2ml tube and blocked in 500ul 
5% bovine serum albumin (BSA) in PBS for 1 hour. Samples were incubated in 500ul of 
anti-D2 antibody dilution in 5% BSA in PBS for 2-3 hours at room temperature. Samples 
were washed in three changes of PBS for 10min each. Samples were then incubated in 
500ul of fluorescent conjugated secondary antibody dilution in 5% BSA in PBS for 45-
60min at room temperature. Samples were washed in three changes of PBS for 10min 
each and placed in chamber mounted on #1.0 borosilicate coverglass (Lab-Tek, catalog 
#155383). Samples were covered with ~150 µL Vectashield mounting medium. Images 
were taken using an inverted standard fluorescence or confocal microscope. 
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Peroxisome Isolation 
Peroxisomes were isolated based on the protocol used for liver peroxisome preparation 
[13-15]. Mouse adipose tissue was dissected freshly and homogenized using Potter-
Elvehjem homogenizer for 5 strokes in ice-cold SEM buffer (250 mM sucrose, 1 mM 
EDTA, 50 mM MOPS, pH7.4). The homogenate was centrifuged at 750 x g for 10 min to 
generate post-nuclear supernatant (PNS). The PNS fraction was then centrifuged at 8500 
x g for 10 min to generate mitochondria enriched pellet (heavy mitochondria pellet, HM). 
The resulting supernatant (heavy mitochondria supernatant, HMS) was then centrifuged 
at 27,000 x g for 20 min to generate peroxisome enriched pellet (light mitochondria pellet, 
LM). The resulting supernatant (light mitochondria supernatant, LMS) was centrifuged at 
100,000 x g, for 45 min to precipitate all the membrane proteins. All centrifugation was 
done under 4°C.  Generated fractions were resuspended in protein sample buffer (PSB, 
30mM Tris base, 10mM EDTA, pH 6.8, 3% SDS, 20% glycerol and 0.00625% 
bromphenol blue) and the protein concentration was determined. 
Protein sample preparation and immunoblotting 
Protein samples in PSB were added with 2% 2-mercaptoethanol and heated to 95 °C for 5 
min before loading. Proteins were size-fractionated on 10% SDS-polyacrylamide gels 
and transferred to nitrocellulose membranes. Membranes were incubated in buffer A (20 
mM Tris, 137mM NaCl, 0.2% Tween 20 and 5% non-fat milk, pH 7.6) for 30 min at 
room temperature. Primary antibodies was diluted in buffer A and incubated with 
membranes for 60 min at room temperature. Membranes were washed 3 times for 5 min 
in buffer B (20 mM Tris, 137mM NaCl and 0.2% Tween 20, pH 7.6). Horseradish 
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peroxidase-conjugated secondary antibodies were diluted in buffer B and incubated with 
membranes for 45 min at room temperature. Membranes were washed 3 times for 5 min 
in buffer B and visualized by enhanced chemiluminescence (SuperSignal West Pico, 
Thermo Scientific). 
Electron microscopy 
Biochemically generated LMt fraction was fixed in 4% paraformaldehyde and washed 3 
times for 5 min with 0.1 M cacodylate buffer. Samples were dehydrated in a series of 
graded ethanol (70% to absolute) and embedded in Epoxy resin. Ultrathin sections were 
inspected after contrasting with electron microscope. 
Wild-type and D2 KO mice were anaesthetized by intraperitoneal injection and perfused 
via the left ventricle with a mixture of 4% paraformaldehyde, 2% glutaraldehyde in 
0.01M cacodylate buffer (pH7.4). Fixed adipose tissue were dissected, cut in slices with 
razor blades, post-fixed in 0.5%, 1%, or 2% glutaraldehyde in cacodylate buffer (pH7.4) 
for 45 min and washed 3 times for 5 min with 0.1 M cacodylate buffer. Fixed adipose 
tissue was embedded into LR White resin (medium grade). LR White-filled gelatin 
capsules were polymerized at 50°C for three days. After preparation of semithin sections 
blocks, ultrathin sections of 80nm were cub, collected on 100 mesh nickel grids and 
therefore coated on the back side with a 1% formvar film. The grids were dried at 37°C 
overnight prior to immunostaining. The sections were incubated with blocking solution (1% 
BSA in TBST) for 30 min at room temperature. Incubation with the primary antibodies 
was performed on droplets with antibodies (anti-D2 and anti-pex19) in 0.5% BSA in 
TBST overnight at room temperature. Thereafter the sections were incubated with a 
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secondary antibodies conjugated with gold particles (12nm particles conjugated with anti-
rabbit antibody and 6nm particles conjugated wit anti-mouse antibody) in 0.5% BSA in 
TBST for 1 hour at room temperature. Negative controls were processed in parallel. The 
grids were rinsed on droplets of TBST and subsequently contrasted with uranyl acetate 
for 2 min and lead citrate for 45 sec. The sections were examined using electron 
microscope. 
Immunoisolation of ABCD2-containing compartment and Shotgun proteomics 
Adipose tissue freshly collected from WT and KO mice was homogenized in ice-cold 
SEM buffer. Homogenates were centrifuged at 750 x g for 10 min in 4°C to generate 
post-nuclear supernatant (PNS). Anti-D2 antibodies were biotinylated (EZ-Link™ Sulfo-
NHS-LC-Biotinylation Kit, Thermo Scientific, prod# 21435) and incubated with 
streptavidin iron beads (MagnaBind™ Streptavidin Beads, Thermo Scientific, 
prod#21344) for 30min in room temperature to prepare antibody-bead complex. The 
complex was then mixed with freshly prepared adipose PNS in 4°C overnight for 
antigen-antibody binding. The mixture was then put under magnetic field to isolate the 
antigen-antibody-bead complexes from other components. The complex was washed 
sequentially with SEM buffer, triton lysis buffer (80 mM NaCl, 50 mM Tris pH8.0, 2 
mM CaCl2, and 1% Triton), triton lysis buffer with 0.5% SDS on ice and triton lysis 
buffer with 0.5% SDS in 37°C. Each eluate was saved and analyzed with western blotting. 
For proteomic samples, only elution with triton lysis buffer with 0.5% SDS at 37°C was 
applied. Eluates were enriched on a SDS-PAGE gel and processed for proteomic analysis.  
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The protein sample was digested with trypsin and the tryptic peptides were analyzed by 
LC-MS/MS using an LTQ Velos Orbitrap mass spectrometer (Thermo Fisher Scientific, 
Waltham, MA) coupled with a Nano-LC Ultra/cHiPLC-nanoflex HPLC system (Eksigent, 
Dublin, CA) through a nano-electrospray ionization source [30]. Tandem MS/MS data 
were acquired using CID fragmentation of selected peptides during the information-
dependent acquisition. The LC-MS/MS results were subjected to protein identification 
and acetylation sites determination using ProteomeDiscoverer 1.3 software (Thermo 
Fisher Scientific, Waltham, MA) and MASCOT server. 
Results 
Immunofluorescent microscopy of ABCD2 protein in mouse adipose tissue 
To determine the distribution pattern of D2 within the adipose tissue and in adipocytes in 
vivo, we localized D2 in adipose tissue explants by indirect immunofluorescence 
microscopy (Fig. 3.1). D2 antibody labeled the thin, cytoplasmic space separating the 
lipid droplet from the cell surface (Fig. 3.1B).  Three dimensional reconstruction of high 
magnification, confocal images revealed a punctate staining pattern dispersed around the 
lipid droplet (Fig. 3.1C and D).  
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Figure 3.1. Immunolocalization of D2 in mouse adipose tissue explants.  Mouse 
epididymal fat pads were fixed with 1% paraformaldehyde, cut into small pieces and 
processed for indirect immunofluorescence microscopy. A and B) Low power (10X) 
images of fixed adipose explants labeled with either pre-immune serum (A) or anti-D2 
polyclonal antibody (B).  C and D) Three dimensional reconstruction of 60 (0.6 mm/slice) 
high power, confocal images (63X) with 0º (C) or 45º rotation (D) along the z-axis. 
Green color denotes D2 labeled with AlexaFluor 488. Blue denotes nuclei stained with 
DAPI. Additional image rotations can be found in supplemental data. 
 
Localization of D2 and selected peroxisome markers in mouse adipose peroxisome 
preparations 
To determine the subcellular localization of D2 protein within the adipocytes, mouse 
adipose tissue was fractionated using a procedure previously published for the isolation 
of peroxisomes from liver (Fig. 3.2A) [285-287]. Mouse adipose tissue was dissected and 
homogenized in detergent free buffer. Sequential centrifugation was used to generate the 
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following fractions: nuclear pellet (NP), post nuclear supernatant (PNS), heavy 
mitochondria pellet (HMt), heavy mitochondria supernatant (HMS), light mitochondria 
pellet (LMt), light mitochondria supernatant (LMS), light membranes (LMbn) and 
cytosol (Cyto). Each fraction was analyzed by western blotting to determine the relative 
abundance of D2 and selected peroxisome markers in each fraction (Fig. 2B). D2, 
catalase, D3 (a.k.a PMP70) and PEX19 were all present in the PNS and HMS fractions. 
However, D2 fractionated with light mitochondria (LMt , 27,000g), while catalase, 
PEX19 and D3 remained in suspension (LMS) and sequentially precipitated with light 
membranes (LMbn, 100,000g). Liver peroxisomes generally co-fractionate with light 
mitochondria and are subsequently separated on a continuous sucrose gradient. However, 
most peroxisome markers in adipose remained suspended and only D2 came down in the 
LMt. This is unlikely due to peroxisome rupture since these markers include D3, a 
protein with multiple membrane spanning segments and that other markers pelleted at 
100,000g. 
Next, we fixed the LMt pellets from both liver and adipose tissue and processed them for 
electron microscopy (Fig. 3.2C). We used liver as a positive control to see evidence of 
both mitochondria (white arrowhead) and peroxisomes (black arrowheads) with their 
characteristic dense matrix and ~0.2um diameter. LMt pellets from adipose also revealed 
mitochondria, but in fewer numbers as well as structures with the typical appearance of 
peroxisomes. However, the fraction was highly enriched with ~0.1um diameter spherical 
structures, with a clearly defined membrane (white and black arrows). Some contained 
evidence of matrix (black arrows), but not as electron dense as peroxisomes typical of 
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liver. With the separation of D2 from catalase and PEX19, we hypothesized that D2 may 
be localized in a subclass of peroxisome in adipocytes.  
 
Figure 3.2. Abundance of D2 and other peroxisome markers in biochemically 
generated fractions from adipose tissue. A) Mouse adipose tissue was homogenized in 
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SEM buffer on ice and sequentially centrifuged using different forces to seperate 
subcellular fractions. B) 2.3% of each fraction was analysed for the abundance of D2 and 
other peroxisome marker proteins by western blotting. The asterisk indicates residual 
signal of D2 from prior blotting. C) Light mitochondrial fractions (LMt) from liver and 
adipose tissues were fixed in 4% paraformaldehyde and immaged using electron 
microscopy. Mitochondria are indicated by white arrowheads. Peroxisomes are indicated 
by black arrowheads. Spherical vesicles with transparent lumen are indicated by white 
arrows. Spherical vesicles with dense matrix are indicated by black arrows. 
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Figure 3.3. Localization of D2 and PEX19 in fixed mouse adipose tissue. A) 
Peroxisome enriched fractions (LMt) were prepared using freshly collected adipose tissue 
from WT and D2 KO mice by sequential centrifugation. The LMt fractions were fixed in 
4% paraformaldehype and embedded in Epoxy resin. Ultrathin sections were cut and 
immunostained using the polyclonal D2 antibody and secondary antibody (cross-linked 
with 6nm diameter gold particles). Peroxisome-like compartments are indicated by white 
arrowheads. B) Fixed mouse epididymal fat samples were cut into ultrathin sections of 
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80nm, immunostained with D2 antibody and secondary antibody (cross-linked with 6nm 
gold particles, indicated by empty arrowheads) and PEX19 antibody and secondary 
antibody (cross-linked with 12nm gold particles, indicated by black arrowheads). 
 
Localization of D2 and PEX19 in fixed mouse adipose tissues 
Next, we prepared LMt fraction from both WT and D2 knock-out (KO) adipose tissue. 
The fractions were fixed and immunostained with D2 antibody and detected by secondary 
antibody cross-linked with gold particles (6nm diameter, Fig. 3.3 A). In the WT sample, 
the D2 antibody specifically labeled compartments (pointed by white arrowheads) with a 
more electron dense center distinct from the surrounding vesicular structures, whereas the 
same compartments were present in the KO sample but not labeled with D2 antibody.  
To determine if the D2 compartment was distinct from the PEX19 compartment in vivo, 
we fixed mouse epididymal adipose explants, cut them into ultrathin sections of 80nm, 
and immunostained them with the D2 and PEX19 antibodies. D2 (white arrowheads) and 
PEX19 (black arrowheads) were detected with secondary antibodies linked with 6nm and 
12nm gold particles, respectively (Fig. 3.3 B). PEX19 and D2 antibodies recognized 
distinct structures and exhibited no overlap in adipose sections.  
Immunoisolation and proteomic profiling of the D2-containing compartment 
We next sought to characterize the proteome of the D2-containing compartment. We 
cross-linked our D2 antibody to biotin and used it to immunoisolate D2-containing 
organelles from mouse adipose homogenates with avidin-coated magnetic beads. The 
immunoisolated compartment was eluted sequentially with buffers containing Triton-X 
100, Triton-X 100 plus 0.5% SDS at 4°C, and the same buffer at 37°C. Eluted fractions 
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were processed by SDS-PAGE and analyzed by western blotting (Fig. 3.4). D2 was 
detected in the starting material (PNS) as well as the supernatant (SupIP) after 
immunocapture, but with much reduced amount. A modest amount of D2 was eluted with 
Triton alone (E1). Solubilization of D2 required the addition of SDS in the elution buffer 
(E2 and E3) and beads. Boiling in SDS under reducing conditions released a small 
amount of residual D2 from the magnetic beads (data not shown). As in the 
centrifugation approach, PEX19 did not co-elute with D2. Calnexin was also blotted as a 
negative control for bulk ER proteins. 
 
 
Figure 3.4. Immunoisolation of the D2-containing compartment. Avidin-coated 
magnetic beads were cross-linked with biotin-conjugated D2 antibody. Mouse adipose 
homogenate (PNS) was incubated with the D2 antibody at 4°C for 16 hours to capture the 
D2-containing compartment. The captured compartment was isolated from the 
supernatant (SupIP) under the magnetic field and sequentially washed by SEM buffer on 
ice (W), triton lysis buffer on ice (E1), triton lysis buffer+0.5% SDS on ice (E2) and 
triton lysis buffer+0.5% SDS under 37°C (E3). Each fraction was analysed for abundance 
of D2, PEX19, LRRC59 and calnexin using western blotting. 
 
We next applied shotgun proteomics to analyze the D2-containing organelles from 
independently prepared WT (n=4) and KO (n=3) adipose tissue. To concentrate proteins 
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in the D2 compartment, we directly eluted in buffer E3 following the wash step. Eluates 
were subjected to mass spectrometry analysis to obtain the D2 associated proteome from 
adipose.  
Any peptides present in KO samples were considered as non-specific associations. 
Uniprot IDs of proteins identified exclusively in the WT samples were analyzed by the 
DAVID functional annotation tool. Proteins associated with D2 were annotated to 
peroxisomal, mitochondrial and ER-related (Table 3.1).  
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Table 3.1. Proteins associated with the D2-containing compartment. The D2-containing 
compartment in adipose homegenates of WT and D2 KO mice was immunoisolated using 
D2 antibody-cross-linked magnetic beads in detergent free buffer. The compartment was 
eluted using triton lysis buffer+0.5% SDS and subjected to mass spectromety analysis. 
Proteins detected exclusively in the WT samples but absent in the KO samples are listed 
in this table. 
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One of the proteins with the strongest association with D2 was LRRC59, which was 
present in all four WT samples. We next re-probed our elution fractions for LRRC59 
(Fig.3.4). LRRC59 was detected in PNS and with much reduced amount in SupIP. A 
modest amount of LRRC59 was present in E1 and E3 and most eluted in E2. These data 
support strong association of LRRC59 with D2 in adipose peroxisomes.  
Discussion 
In this study, we have shown that D2 is localized in a subclass of peroxisomes that is 
potentially associated with mitochondria and ER in mouse adipose tissue. To the best of 
our knowledge, this is the first report that describes the subcellular localization of D2 in 
mouse adipose tissues.  
Our findings indicate that the D2-containing compartment harbors peroxisomal proteins 
but at the same time lacks some of the well-established markers, therefore distinguishing 
itself as a subclass of peroxisomes. As early as 1980, the concept of ‘microperoxisomes’ 
was proposed with evidence showing their close association with lipid droplets and ER in 
cultured adipocytes [203]. However, their biological characteristics and functions in 
adipose tissue have long remained undescribed. In recent years, there has been 
reemerging interest in the study of these organelles with the discovery that peroxisome 
dysfunction leads to a series of adipose phenotypes [253, 254]. These findings are 
generally obtained from peroxin deficient mouse models in which peroxisomal 
membrane protein assembly is disrupted. In these studies, peroxisomes were not further 
categorized and no attempt was made to assess tissue-specific effects of peroxisome 
dysfunction. Our results suggest the existence of distinct subclasses of peroxisomes 
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within adipose, suggesting that even within a given tissue, peroxisome function may be 
differentially affected. 
D2 has been shown to play essential roles in lipid metabolism [241, 248, 282, 283]. 
However, D2 is not highly expressed in tissues characterized with high rates of -
oxidation metabolisms, such as liver, heart or skeletal muscle, but is most abundant in 
white adipose tissue [241]. Given that white adipose is far less metabolically active and 
contains fewer peroxisomes than liver, the need for such high levels of D2 in adipose is 
unclear. D2 has been shown to be critical for erucic acid catabolism in mice [283]. 
However, erucic acid is present in trace amounts in most plant and seed oils, suggesting 
other essential functions of D2 in endobiotic and xenobiotic metabolism [283]. Given the 
distinct substrate specificities of peroxisomal transporters, the D2-compartment may 
differ from other peroxisomes with its unique substrate selection. 
Our findings suggest a close relationship between D2-containing peroxisomes and 
mitochondria and ER. Using immunoisolation approach combined with mass 
spectrometric, we purified a D2 containing compartments from adipose tissue and 
determined its proteomic profile. Besides peroxisomal proteins, we also identified 
mitochondrial and ER proteins. This is consistent with emerging evidence indicating that 
peroxisomes, mitochondria and ER may be physically associated with each other [210, 
288]. Peroxisomes share key components of division machinery with mitochondria in 
both mammalian cells and yeast [289, 290]. The movement of peroxisomes is coupled 
with mitochondria but independent of cytoskeleton during cell division in yeast [291]. 
Peroxisomes derive a portion of their components from mitochondria through a vesicular 
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transport pathway [292]. The physiological function of this pathway is still unknown, but 
might involve the transport of lipid metabolites and proteins.  
There is also growing evidence suggesting that peroxisomes may form out of ER in a 
‘budding’ pattern and derive some of their proteins and membranes through this 
mechanism [210]. Vesicles originating from ER were shown to be routed to peroxisomes 
with the assistance of Pex16 or Pex3 and the ER budding factor Sec16b in human 
fibroblasts [293-295]. These vesicular structures were referred as ‘preperoxisomes’ and 
two biochemically distinct populations have been identified [210]. Preperoxisomes must 
fuse with other more mature peroxisomes to generate functional organelles [210, 296]. 
Therefore, there are at least four subpopulations of peroxisomes present within a cell: the 
two distinct preperoxisomes, the more mature but not fully functional peroxisomes, and 
the fully mature and functional peroxisomes. However, no attempt has been made to 
characterize the complete proteomes of these organelles. The D2-containing peroxisome 
in adipose may be categorized into one of the first three subgroups or even distinguish 
itself as another subclass of peroxisomes unique to adipocytes.  
Finally, we observed that the putative trafficking protein, LRRC59, is closely associated 
with D2-containing compartment. The biological function of LRRC59 is still poorly 
understood. A recent report indicates the interaction of LRRC59 with Selenoprotein S 
(SelS), an ER protein involved in the protein retro-translocation from ER to cytosol and 
the inflammatory response [297-299]. However, the influence of LRRC59 on SelfS 
functions was not further investigated [299]. Nonetheless, their interaction indicates a 
potential role of LRRC59 in the trafficking vesicles originating from the ER. The 
interaction of LRRC59 and D2 suggests the possible origin of some components of the 
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D2-conatining peroxisome from the ER. Another group reported that LRRC59 facilitates 
the intracellular trafficking of fibroblast growth factor 1 (FGF1) into nucleus in cultured 
cells [284]. Given the importance of FGF1-PPAR signaling axis in adipocyte 
metabolism, LRRC59 may be essential for normal adipose functions [300]. Its 
association with D2 may potentially bridge D2 dependent lipid metabolism and FGF1 
signaling in adipose tissue.  
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CHAPTER 4. SUMMARY AND CONCLUSION 
Of the three identified peroxisomal ABC transporters, ABCD2 is the only one whose 
functions are still largely unexplored and deserving of more attention.  Two fundamental 
questions need to be addressed to better characterize this transporter: What is its function? 
Where is it located intracellularly? The work presented in this dissertation will provide 
some valuable hints on the answers.  
The first goal of studies was to determine the role of D2 in modulating PPAR signaling 
and the impact of D2 on response to PPAR agonist treatment. First, we studied the 
impact of D2 on response to PPARagonist fenofibrate treatment in normal mouse 
model. Based on the microarray analysis, we discovered that various gene pathways were 
differentially influenced by D2 genotype and fenofibrate. One of the most influenced 
pathways was the PPAR signaling pathway. Although D2 has long been known as a 
PPAR target gene, this is the first report to show that lack of D2 reciprocally impacted 
on PPARsignalingNext, we examined the effect of D2 on fenofibrate response in 
cultured 3T3-L1 adipocytes. Fenofibrate treatment induced the expression of PPAR and 
some of its downstream target genes. This response was blunted by loss of D2 in D2 
deficient cells, suggesting D2 modulates genomic response to fibrate by influencing the 
expression of some of the genes in PPAR signaling pathway. Then, we evaluated the 
influence of D2 on the lipid-lowering effects of fenofibrate in a mouse model of diet 
induced obesity. Fenofibrate was effective in controlling the body weight and plasma 
lipid profiles. Interestingly, the TG secretion rates in D2 KO mice were significantly 
lower in both treated and control groups. However, it was not sufficient to alter the 
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overall effects of fenofibrate therapy. Lastly, we looked at the relationship of D2 
polymorphism and fenofibrate hypolipidemic effects in humans, but detected no 
significant correlation. 
Our studies have clearly demonstrated the importance of D2 in modulating 
PPARsignaling. To the best of our knowledge, this is the first report to demonstrate the 
reciprocal impact of D2 on PPAR signaling. D2 dependent lipid metabolism may 
impact the endogenous lipid pool and therefore alter the available ligands for PPAR. 
The differences between genotypes in measured parameters were more evident in 
untreated group, suggesting the influence may be masked when exogenous ligands are 
present with considerable amount.  
A second goal of studies was to determine the subcellular localization of D2 in mouse 
adipose tissue and to characterize the D2-containing organelle.  
First, we examined the intracellular distribution of D2 within mouse adipocytes using 
immunofluorescent microscopy. D2 has been known to be most abundantly expressed in 
adipose tissues. In this study, we discovered a punctuate pattern of D2 distribution 
surrounding the central lipid droplets within adipocytes. Next, we determined the 
subcellular localization of D2 using a biochemical approach and discovered that the D2 
enriched subcellular fraction didn’t have some well-established peroxisomal markers 
such as catalase and pex19. This indicates D2 may be localized to a subclass of 
peroxisomes that didn’t harbor those markers. Then, using histological and gold labeled 
immunostaining approach, we verified the distinct localizations of D2 and Pex10 in intact 
mouse adipose. Lastly, we isolated the D2-containing peroxisome from adipose 
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homogenates and analyzed its proteomic profile. We discovered a close relationship 
between this subtype of peroxisome and mitochondria and ER.  
Our studies have demonstrated the subcellular localization of D2 in a subclass of 
peroxisomes. These peroxisomes have a typical structure of microperoxisomes under the 
electron microscope but lack some well-established marker proteins. These 
characteristics distinguish it as a unique subclass of peroxisomes that have not been 
reported before. Proteomic analysis revealed their association with other subcellular 
organelles including mitochondria and ER. With all the emerging evidence indicating 
metabolic interplay between these organelles, our findings emphasize the necessity for 
further investigation of peroxisome dynamics and metabolisms.  
In conclusion, the research demonstrated a novel role of D2 in modulating PPAR 
signaling and fenofibrate response both in vitro and in vivo. The studies also revealed the 
existence of D2-containing compartments in mouse adipose tissue that potentially 
represents a subclass of peroxisomes. Further investigation is necessary to elucidate the 
mechanism by which D2 influences PPAR signaling and to further characterize the D2-
containing peroxisome and its relation with other subcellular organelles.  
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